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Abstract 
Inclusion body myopathy associated with Paget’s disease of bone and frontotemporal 
dementia (IBMPFD; OMIM 167320) is an autosomal dominant inherited multisystem 
disorder caused by mutations in the valosin-containing protein (VCP) gene.  Knock-in mice 
expressing the common human p.R155H VCP mutation develop a progressive myopathy 
with ubiquitin-positive inclusion bodies, accumulation of abnormally shaped mitochondria 
in skeletal muscle and focal bone degradation reminiscent of Paget’s disease of bone. To 
further assess the physiological effects of this mutation in muscle, we compared the in vitro 
contractile properties of the extensor digitorum longus (EDL) (fast-twitch muscle) and 
soleus (slow-twitch muscle) from mice heterozygous for the p.R155H mutation in VCP and 
wild-type mice. Our results showed that fast-twitch muscle fibres isolated from VCPR155H/+ 
mutant mice ~12-15 months old not only fatigued faster and to a greater extent, but also 
recovered significantly slower and to a lesser degree than those of age-matched wild-type 
mice. Thereafter, the muscles seem to recover and by the time the mice were 27 months 
old, there was no difference in the fatigue resistance of mutant and wild type mice. These 
results suggest that VCP may be necessary for maintenance of glycolytic capacity in mouse 
fast-twitch muscle fibres at 12-15 months only. Investigation of oxidative capacity in 12 and 
14 month old VCPR155H/+ mice revealed significantly lower mitochondrial enzyme activity 
(citrate synthase) in VCPR155H/+ mice at 14 months; concomitant with the reduction in fast-
twitch fibre fatigue tolerance. Primary fibroblast cells isolated from our VCPR155H/+ mouse 
model showed reduced ability of mitochondrial networks to fragment when exposed to 
oxidative stress, indicating that intact VCP is required for the successful maintenance of 
mitochondrial network dynamics and quality control.  
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Introduction 
 
1.1 Inclusion body myopathy associated with Paget’s disease of bone 
and frontotemporal dementia 
 Inclusion body myopathy (IBM) associated with Paget’s disease of bone (PDB) and 
frontotemporal dementia (FTD), hereafter referred to as IBMPFD, is an autosomal-
dominantly inherited multi-system disorder (OMIM 167320) that results in premature 
death in patients. The disease is characterised by three pathological phenotypes of varying 
penetrance – progressive adult-onset proximal and distal myopathy; early-onset PDB and 
premature neurodegenerative FTD.  
 Despite its characterisation as a multi-system disorder, the phenotype is variable in 
how it manifests (both within affected families and between families), where the muscle 
weakness or myopathy is the most common symptom seen in 90% of affected individuals 
(Kimonis et al., 2008). Disabling weakness is observed at approximately 45 years of age in 
90% of patients, and 47% of patients develop osteolytic lesions congruent with PDB at a 
similar age. 37% of patients present with premature FTD at a mean onset of 54 years of 
age, manifested by prominent behavioural and language dysfunction (Weihl et al., 2009). 
Figure 1.1 summarises the relative pathologic penetrance of each symptom of IBMPFD.   
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Figure 1.1 Varying symptomatic presentation in affected individuals. IBM: inclusion body 
myopathy; PDB: Paget’s disease of bone; FTD: frontotemporal dementia (Data adapted 
from Pagon et al., 2011) 
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 The familial concurrence of neuromuscular disorder and Paget’s disease of bone 
was originally observed in the mid-20th century, when Caughey (1957) described three 
brothers suffering from “dystrophia myotonica”, two of whom also suffered from Paget’s 
disease. The diagnoses were based on the presentation of typical physiological features of 
dystrophia myotonica; neck and limb muscle hypertrophy lacking a proportional increase in 
muscle strength, mechanical myotonia of the tongue, general muscular stiffness and an 
inability to relax ones grip. In the two individuals suffering from Paget’s disease, histological 
analysis revealed the disorganised mosaic pattern of the trabecular bone typical of the 
disease (Caughey, 1957). 
 Patients were diagnosed with IBMPFD if they presented with two or more of the 
clinical symptoms; however this classification preceded the discovery of the causal genetic 
mutation.  In patients, the diagnosis of IBM is based on skeletal muscle histology, serum 
creatine phosphokinase (CK) concentration and electromyogram. Paget’s disease of bone 
diagnosis is based on serum alkaline phosphatase (ALP) concentration, pyridinoline (PYD) 
and deoxypyridinoline (DPD) concentration in the urine, and radiographic or radionuclide 
scintigraphic scanning of the skeleton. The diagnosis of frontotemporal dementia is based 
on extensive neuropsychological assessments.  
 Each of the three pathophysiological symptoms may present in isolation, however 
the concurrence of both a limb-girdle muscular dystrophic (LGMD) and Pagetic phenotype 
was described by Kimonis and colleagues to be a genetically distinct disorder in 2000, with 
the researchers finding both symptoms present in eight out of eleven family members 
(Kimonis et al., 2000). Bone X-rays revealed coarse trabeculation, sclerotic or hardened 
areas and thickening of the cortical regions of the pelvis, spine, skull and shoulder. 
Myopathic degeneration presents as adult-onset distal and proximal muscle weakness, 
with the hip and shoulder girdle muscle groups being initially involved.  Winging of the 
scapula may be observed in some cases (Dec et al., 2014). IBMPFD patients display an 
abnormal, waddling gait and are unable to raise the arms due to the effects of the disease 
on the hip and shoulder girdle muscles. Clinically, normal neural conduction, myopathic 
electromyogram and a generalized reduction in tendon reflexes is noted (Kimonis et al., 
2008). The disease progresses to “wheelchair confinement, quadriparesis, bedfastness, 
respiratory failure, cardiac failure and death in the 40s-60s” (Kimonis et al., 2000). Chronic 
respiratory failure due to muscle weakness is the primary cause of death in IBMPFD 
patients, as well as in other myopathic conditions (Selva-O’Callaghan et al., 2000).  
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 Variable pathological features are seen in skeletal muscle biopsies of IBMPFD 
patients. Light microscopy reveals nonspecific changes in muscle biopsies; such as fibre size 
variability, predominance of type I fibres, and both fibre atrophy and hypertrophy. Fibres 
may contain single or numerous vacuoles. Rimmed vacuoles and VCP- and ubiquitin-
positive inclusion bodies are seen in muscle fibres, which are characteristic of IBM. As the 
disease progresses, extensive degeneration of the muscle occurs, with associated fatty 
replacement of muscle tissue in severe cases (Hübbers et al., 2007).  
 Paget’s disease of bone is a chronic focal bone disorder which presents in 
approximately 45% of IBMPFD patients. The disease is suspected in individuals with bony 
tenderness, spine or hip pain, pathologic fractures and long- or cranial-bone deformity. 
Hearing loss may also occur as a result of compression of the vestibulocochlear nerve 
caused by calvarial bone overgrowth. Serum ALP concentration is elevated (Pagon et al., 
2011). The primary pathology manifests as increased resorption and deposition of highly 
disorganised and poor quality bone, which increases susceptibility to fracture. The 
imbalanced bone turnover rate is due to the increased bone resorbing capacity of 
osteoclasts in localised areas. Histological investigations reveal abnormally large, 
multinucleated osteoclasts with nuclear inclusions (Kimonis et al., 2008; Nalbandian et al., 
2011). The mean age of onset of PDB in IBMPFD patients is 45 years.  
 The early symptoms of FTD include dyscalculia, dysnomia, paraphasic errors and 
comprehension deficits, with relative preservation of memory. Later stages are 
characterised by loss of speech, alexia, agraphia and deficient auditory comprehension 
(Nalbandian et al., 2011). The preservation of memory serves to discriminate between FTD 
and Alzheimer’s disease (Kovach et al., 2001; Kimonis et al., 2008; Nalbandian et al., 2011; 
Pagon et al., 2011). In addition, FTD patients display cerebral atrophy in the frontal and 
anterior temporal lobes, rather than the posterior temporal, hippocampal and parietal 
atrophy typical of Alzheimer’s disease (Forman et al., 2006; Kimonis et al., 2008). 
Histologically, patients with IBMPFD-associated FTD display a novel pattern of ubiquitin 
pathology which is distinct from other variants of frontotemporal lobar degeneration with 
ubiquitin-positive inclusions (FTLD-U). Specifically, abundant intranuclear ubiquitin-positive 
inclusions, and dystrophic neurites are seen, primarily in the neocortex (Forman et al., 
2006).  
 A genome-wide screen of four unrelated IBMPFD families in the U.S revealed 
linkage to chromosome 9, and IBMPFD was found to localise to a 1.08-6.46 cM critical 
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interval on chromosome 9p13.3-12 (Kovach et al., 2008). Further investigations using a 
candidate-gene approach uncovered six heterozygous missense mutations in the valosin 
containing protein, or VCP gene in 13 families with IBMPFD linked to chromosome 9, thus 
identifying an underlying genetic cause of IBMPFD (Watts et al., 2004). To date, over 21 
mutations in the VCP gene have been identified (Meyer and Weihl, 2014). These mutations 
are listed in Table 1.1. Pathogenic variants in the VCP gene have been identified in the 
majority of families with IBMPFD that link to chromosome 9p, yet several families have 
been identified that meet the diagnostic criteria for IBMPFD who do not harbour an 
identifiable pathological variant of VCP and have not shown linkage to chromosome 9.21.2, 
suggestive of genetic heterogeneity in IBMPFD (Waggoner et al., 2002). Since the 
identification of the VCP mutation common to the majority of families with IBMPFD, 
studies have indicated that up to 10% of VCP-confirmed IBMPFD patients had previously 
been diagnosed with amyotrophic lateral sclerosis (ALS; Johnson et al., 2010, Kimonis et al., 
2008), a neurodegenerative disease which manifests as upper and lower motor neuron 
dysfunction and leads to rapidly progressive paralysis and respiratory failure. Ubiquitin-
positive inclusions and pathological TAR DNA-binding protein (TDP-43) aggregates are seen 
in the motor neurons, similar to those seen in the skeletal muscle and brain tissue of 
IBMPFD patients (Weihl et al., 2008). Studies have broadened the spectrum of the IBMPFD 
phenotype to include motor neuron degeneration, and it is postulated that mutations in 
VCP may account for 1-2% of familial ALS (Johnson et al., 2010). 
 Since the discovery of VCP mutations in IBMPFD patients, much research has been 
conducted to elucidate the molecular pathways involved in the progression of the disease. 
Unfortunately, at present, there are no known cures or treatments for the disorder (Chan 
et al., 2012). 
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Table 1.1 VCP mutations identified in patients with IBMPFD. Mutations have been 
predominantly identified within the CDC48 N-terminal domain, the N-D1 Linker region (L1) 
and D1 ATPase domain (outside of the catalytic domain).  
 
 
 
 
 
 
 
 
 
 
 Amino acid Base change (ORF) Exon Domain No. of families 
1  I27V 79A>G 2 N terminus 1 
2  R93C 277C>T 3 N terminus 4 
3  R95G 283C>G 3 N terminus 2 
4  R95C 283C>T 3 N terminus 1 
5  P137L 410C>T 4 N terminus 1 
6  R155C 463C>T 5 N terminus 5 
7  R155H 464G>A 5 N terminus 8 
8  R155P 464G>C 5 N terminus 1 
9  R155S 463C>A 5 N terminus 1 
10  R155L N/A 5 N terminus 2 
11  G157R 469G>C 5 N terminus 1 
12  G156S 466G>A 5 N terminus 1 
13  R159H 476G>A 5 N terminus 2 
14  R159C 476G>A 5 N terminus 2 
15  R191Q 572G>A 5 Linker 1 1 
16  L198W 593T>G 6 Linker 1 2 
17  I206F 828A>T 6 Linker 1 1 
18  A232E 695C>A 6 L1-D1 Junction 1 
19  T262A 784A>G 7 AAA D1 1 
20  N387H 1159A>C 10 AAA D1 1 
21  A439S 1351G>T 11 Linker 2 1 
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1.2 VCP structure 
 Valosin-containing protein, or VCP (p97 in mice, TER94 in Drosophila melanogaster 
and CDC48 in Saccharomyces cerevisiae) is a 97-kDa, highly conserved member of the type 
II AAA+ (ATPase associated with diverse cellular activities) ATPase family (Ju and Weihl, 
2010). Proteins in the AAA+ ATPase superfamily typically assume hexameric conformation 
in the cytosol and harness the energy from ATP hydrolysis to perform macromolecular 
remodelling. VCP is found in all cells in the body, comprising 1% of the total cellular protein 
in yeast (Yamanaka et al., 2011). The protein was first isolated from pig intestine in 1987 
(Koller and Brownstein, 1987). 
 In a similar manner to other AAA+ protein family members, VCP operates as an 
enzymatic motor, using the energy from ATP hydrolysis to perform mechanical work in the 
cell, by binding co-factors and substrates and remodelling its confirmation to unfold or 
extract target substrates.  Each VCP monomer consists of an N-terminal domain, two highly 
conserved central ATPase domains, D1 and D2, and a C-terminal region. The N-domain and 
D1 domain are joined by a flexible linker region, L1, while the D1 and D2 domains are 
connected by a second linker region, L2 (Wang et al., 2003). The ATPase domains comprise 
Walker A and B domains, which serve to bind and hydrolyse ATP.  The globular N-terminal 
domain, shown to be the least conserved region in the AAA+ family of proteins, is believed 
to be the determining factor in target-binding specificity, and mediates the binding of both 
adaptor proteins and ubiquitinated protein substrates (Wang et al., 2004).  
 The distinct cellular functions of VCP are tightly regulated by a diverse number of 
cofactors. Two classes of cofactors can be distinguished - substrate-recruiting cofactors 
serve as adaptor proteins for substrates, and dictate their binding to VCP. In contrast, 
substrate-processing cofactors control the ubiquitylation state of substrates following their 
recruitment to VCP (Böhm et al., 2011). For example, the N domain is known to facilitate 
the heterotrimeric complex formation of VCP with two adaptor proteins; ubiquitin fusion 
degradation 1 (Ufd1) and nuclear protein localization 4 (Npl4) (Pye et al., 2007). It has been 
proposed that the VCP-Ufd1-Npl4 complex recognizes and extracts ubiquitinated 
substrates from either the endoplasmic reticulum (ER) lumen or ER membrane, and 
shuttles them to the cytoplasm for proteosomal degradation (Ye et al., 2001; Ju and Weihl 
(Review) 2010).  VCP is known to bind directly to substrates and cofactors which contain 
the ubiquitin regulatory X domain (UBX) (Dreveny et al., 2004(ii)); however this domain is 
not a prerequisite for VCP interaction and binding. Table 1.2 comprises a non-exhaustive 
list of VCP-interacting proteins and their functions. 
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Table 1.2 Classification of VCP interacting proteins based on structural or general functional 
characteristics 
 
Structural/functional 
criteria 
VCP interacting 
protein 
Function 
Ubiquitin regulatory X 
(UBX) domain 
Ubx2 
Links VCP to ERAD 
  
p47 
Essential for VCP-mediated post-mitotic Golgi 
reassembly 
  VCIP135 Involved in VCP/p47-mediated membrane fusion 
  
Cui3p 
Required for normal proteolysis and sporulation in 
yeast cells 
  
Cui2p 
Required for normal proteolysis and sporulation in 
yeast cells 
  
Cui1p 
Required for normal proteolysis and sporulation in 
yeast cells 
DNA/RNA repair 
WRN 
VCP/WRN complex translocates from nucleolus 
upon DNA damage 
  TB-RBP Implicated in DNA recombination and repair events 
  DUF DNA unwinding factor, involved in DNA replication 
  
BRCA1 
Participates in DNA repair, transcription and 
transcription-coupled DNA repair 
Protein degradation 
Ubiquitin 
Small regulatory protein which targets substrates 
for degradation 
  
Ufd2 
Substrate-processing cofactor of VCP involved in 
multi-ubiquitination 
  
Ufd3 
Substrate-processing cofactor of VCP involved in 
multi-ubiquitination 
  Proteasome Degradation of ubiquitinated substrates 
  
Ufd1-Npl4 
Retrotranslocation of poly-Ub peptides from the ER 
to the cytosol; spindle disassembly 
Mitosis 
Ase1 
Spindle disassembly processes during mitosis-to-
interphase transition 
  
Cdc5/Plx1 
Spindle disassembly processes during mitosis-to-
interphase transition 
Membrane traffic SVIP Potential involvement in membrane trafficking 
  
SYT I, II 
Membrane trafficking; SYT I required for Ca
2+
 
triggering of exocytosis 
  Clathrin Receptor-mediated endocytosis and Golgi sorting 
Others 
EMeg32 
Glucosamine-6-phosphate acetyltransferase; 
localises with VCP at Golgi 
 Ex-polyQ Expanded polyglutamine repeats 
 
Ataxin-3 
VCP binds via ex-polyQ region of ataxin-3; 
proteasome-associated factor involved in Ub-
protein degradation 
  
HDAC6 
Nucleo-cytoplasmic shuttling, Ub-binding protein; 
deacetylates lysine residues 
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 VCP exists as a homohexamer in the cell (Figure 1.2; Pye et al., 2006; Mori-Konya et 
al., 2009). The association of ATP with the D1 domain drives the formation of stable VCP 
homohexamers, whereas the D2 domain is largely responsible for ATP hydrolysis (Halawani 
et al., 2008; Ju et al., 2010). Cryo-electron microscopy and crystallography studies showed 
that the D1 and D2 ATPase domains of the VCP hexamer form two stacked rings 
surrounding a central channel or pore (DeLa Barre and Brunger, 2003; Pye et al., 2006). It is 
unclear at present whether remodelling of substrates by VCP involves their complete or 
partial insertion through this central channel (Meyer and Weihl, 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
21 
 
 
 
 
 
Figure 1.2. Schematic representation of protein and domain structure of VCP. (A) The 
single VCP protomer is coloured grey, the N domain is depicted in red, and the D1 and D2 
ATPase domains are orange and cyan, respectively (From Pye et al., 2006). The D1 and D2 
ATPase domains of the VCP hexamer form two stacked rings surrounding a central channel 
or pore. (B) The CDC48 region, located in the N-terminal domain, has been identified as a 
mutation ‘hotspot’. The L1 linker region, which connects the N domain to the D1 ATPase 
domain, is also susceptible to missense mutations. Mutations of the arginine residue at 
codon 155 comprise the most encountered mutation in IBMPFD patients. 
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  The conformation of the N-domain and linker region with respect to the D1 and D2 
regions relates directly to the ATPase activity of VCP (Niwa et al., 2012). The N-terminal 
domain is positioned on the periphery of the D1 ring and the two are connected by a 
flexible 20 amino acid L1 linker region. This flexible linker region allows the hexamer to 
adopt one of two possible conformations, either coplanar or flexible (Figure 1.3). Hydrolysis 
of ATP by the D2 domain is thought to be the primary driving force by which the domain 
conformation of VCP is rearranged. This rearrangement results in the structural 
remodelling of specific target substrates. During the ATPase cycle, ATPase activity is 
supressed when the coplanar conformation is adopted between the N-domain and the D1 
domain (Figure 1.3). However, when the N-domain is released from the D1 plane, D2-
mediated ATP hydrolysis is possible and ATPase activity is increased. Studies have reported 
increased ATPase activity of disease-associated VCP mutants, with a 3-fold increase in ATP 
hydrolysis by VCP-R155P and VCP-A232E observed (Halawani et al., 2009). 
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Figure 1.3. Structural model of VCP N-domain flexibility. During the ATPase cycle, VCP has 
the ability to adopt two conformations. When the N-domains are coplanar with the D1 ring, 
ATP hydrolysis is prevented. However, when the flexible conformation is adopted, ATP 
hydrolysis is facilitated by the compact ring formation of the D2 domains. The A232E 
mutation in the L1-D1 junction, is suggested to have a destabilizing effect on the N and D1-
domain interaction due to steric hindrance, thus preventing the N and D1-domains 
assuming the coplanar conformation. Only two of the six monomers in the hexamer are 
shown for clarity (From Yeung et al., 2014). 
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 Of note, familial studies have shown that, while R155H is the most common 
mutation in IBMPFD patients, the base change mutation of alanine to glutamic acid (A232E, 
codon replacement of GCA with GAA) at amino acid position 232 in VCP results in a more 
severe pathological presentation, specifically a more aggressive myopathy and earlier onset 
of Paget’s disease (Watts et al., 2004).  Interestingly, the A232E mutation was suggested to 
have a destabilizing effect on the N and D1-domain interaction due to steric hindrance, 
thus preventing the N and D1-domains assuming the coplanar conformation, which 
resulted in increased ATP hydrolysis by VCP (Niwa et al., 2012).  
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1.3 VCP functions  
 Many cellular activities require the involvement of VCP, both as a chaperone 
protein and also in molecular complex formation. These activities include ER-associated 
degradation, nuclear envelope reformation, post-mitotic Golgi reassembly, cell cycle 
control and membrane fusion (Rabinovich et al., 2002; Rabouille et al., 1998; Alzayady et 
al., 2005; Fröhlich et al., 1991). These functions are at least partially regulated by the 
ubiquitin-proteasome system (UPS), in which VCP, acting as a molecular segregase,  binds 
both poly-ubiquitinated proteins and ubiquitin-interacting proteins in order to facilitate 
their delivery to and subsequent degradation by the 26S proteasome (Pye et al., 2007; 
Halawani et al., 2009; Ju and Weihl, 2010).  
 In addition to the relatively well categorised role of VCP in the shuttling of cargo for 
proteasomal degradation, studies of IBMPFD patient tissue suggest the possible 
involvement of VCP in autophagy (Vesa et al., 2009; Ju et al., 2010; Tresse et al., 2010). VCP 
interacts with misfolded aggregated proteins and structurally alters them in order to unfold 
or extract them, thus allowing them to be trafficked to either a proteasomal or autophagic 
fate (Bug and Meyer, 2010; Ju and Weihl, 2010). The term autophagy, from the Greek 
words ‘phagy’ (eat) and ‘auto’ (self), describes the evolutionarily conserved, homeostatic 
pathway by which cytoplasmic components are sequestered into a double-membrane 
vesicle, the autophagosome, which fuses with the lysosome to facilitate the degradation of 
its cargo by hydrolases (Figure 1.4). The process is generally activated during times of 
nutrient starvation, in order to catabolise non-essential macromolecules, however, it has 
also been associated with physiological and pathological pathways, such as development, 
cellular differentiation, stress, infection, cancer and neurodegenerative disorders 
(Mizushima and Levine, 2010; Codogno et al., 2012). The resulting micronutrients and 
molecules are redirected to locations/processes where their requirement is immediate and 
vital for cellular survival.  
 In addition to this protective function, ‘quality control’ autophagy describes the 
basal autophagic pathways by which long-lived/misfolded proteins or dysfunctional 
organelles are shuttled to the autophagosome. These pathways may be further categorized 
based on the autophagic substrates involved, for example macroautophagy (degradation of 
cytoplasmic material, Figure 1.4), ribophagy (ribosomes) and mitophagy (mitochondria) 
(Bug et al., 2012).  
 
26 
 
 
 
Figure 1.4 Schematic diagram of macroautophagic degradation. Under autophagy-
inducing conditions, initiation of autophagy involves the formation of the phagophore (a 
membranous cistern-like structure) facilitated by the recruitment of an autophagy-related 
protein complex (ATG12-ATG5-ATG16L1) and LC3. Expansion of the phagophore allows 
engulfment of cytosolic components, including long-lived and dysfunctional organelles, 
protein aggregates and foreign organisms (viruses and bacteria). The autophagosome is 
formed when the expanding phagophore closes to form the typical double-membrane 
vesicular structure. The fusion of lysosomes with autophagosomes allows the entry of 
hydrolytic enzymes which then degrade the cargo, providing basic metabolites for use in 
the cell. VCP is believed to be involved in aggregation of autophagic protein cargo and 
autophagosome maturation, as the presence of VCP mutation results in the accumulation 
of immature autophagosomes. 
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 Selective autophagic adaptor proteins, such as p62 and neighbour of Brca1 (Nbr1), 
recognize and form complexes with the ubiquitinated proteins/organelles that have been 
selected for degradation (Johansen and Lamark, 2011).  Once the substrate-adaptor protein 
complex associates with LC3-II - the autophagosomal membrane-bound, lipidated form of 
the autophagic marker LC3 - the cargo is incorporated into the autophagic vesicle. The 
autophagosome then fuses with the lysosome and the engulfed content is degraded by 
lysosomal proteases and hydrolases (Weidberg et al., 2011). LC3-II lipidation and 
accumulation in cells is generally used as a measure of autophagic flux, with an increase in 
the ratio of LC3-I to LC3-II conversion indicative of an upregulation of autophagy 
(Mizushima and Levine, 2010). 
 It was discovered that, under steady-state growth conditions, LC3-II and p62 levels 
were higher in mutant myoblasts obtained from IBMPFD patients than wild-type VCP 
controls, indicating a possible augmentation in the rate of autophagic turnover (Tresse et 
al., 2010).  Further analysis showed that the increase in intracellular autophagic marker 
proteins was accompanied by an accumulation of immature autophagosomes. Small 
interfering (si)RNA knock-down of VCP, or the expression of the dominant-negative ATPase 
deficient mutant, VCPE578Q, showed similar increases in LC3-II, p62 and immature 
autophagosome accumulation (Ju et al., 2009). However, these autophagosomes failed to 
localise with lysosomes. This finding suggested an impairment of autophagosome-lysosome 
fusion and subsequent autophagic substrate degradation in IBMPFD patients, an effect that 
has been replicated in vitro (Tresse et al., 2010).  
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1.4 Mouse models of IBMPFD 
  In patients, the VCP mutation is expressed in an autosomal dominant manner, 
resulting in ubiquitous expression of mutated VCP protein. Heterozygous VCP+/- mice 
lacking one functional allele were found to be indistinguishable from wild-type littermates 
(Müller et al., 2007). Histological analysis of muscle tissue from the VCP+/- mouse revealed 
irregularities in muscle fibre size and organization, increases in endomysial connective 
tissue and the presence of small, linear, basophilic ‘rimmed cracks’, resembling the 
pathology in IBMPFD patients. In order to examine the effects of mutated VCP-R155H 
expression in muscle tissue specifically, Weihl and colleagues (2007) generated a transgenic 
overexpression mouse model, which expressed the VCP-R155H allele under a skeletal 
muscle-specific creatine kinase promoter. These mice displayed progressive muscle 
weakness beginning at around six months of age, recapitulating, at least in part, the 
myopathy associated with IBMPFD. Mice homozygous for the R155H mutation exhibit 
accelerated pathology and typically die between post-natal days 14-21, due to severe 
muscle, spinal cord and cardiac pathology (Nalbandian et al., 2012). Indeed, in our lab, we 
found that homozygous VCPR155H/R155H mice were extremely difficult to generate. 
Heterozygous knock-in expression of VCPR155H/+ in the mouse model results in a slower 
onset of disease pathology at approximately 6-9 months of age, thus enabling researchers 
to examine the cumulative age-dependent functional and pathological effects of VCP 
mutation in the adult and aged animal (Badadani et al., 2010; Nalbandian et al., 2013a).  
 Cytoplasmic and nuclear accumulation of proteinaceous inclusions is seen in 
myofibrils of the VCPR155H/+ mouse – a hallmark of the human disease (Weihl et al., 2007). 
VCPR155H/+ mice gain mass at the same rate as wild-type littermates as they age. From 
approximately six months of age onwards, however, progressive muscle weakness was 
observed in the forelimbs of the mutant mice, as determined by a grip strength test. 
Rotarod testing, involving timed running on a horizontal rotating rod, was also 
implemented in order to assess motor coordination, endurance and fatigue, with results 
also showing reduced performance in mutant mice.  
 The VCPR155H/+ mouse is of particular importance as a tool of research, as the 
substitution of the arginine residue with a histidine moiety (base pair change of CGC to 
CAC) at the amino acid position 155 is the most encountered VCP mutation linked to 
IBMPFD (Watts et al., 2004). Both human and murine VCP comprises 806 amino acids, with 
the homologues differing by a single amino acid residue at the 684 position (Müller et al., 
29 
 
1999). Numerous studies have explored the molecular spectrum of pathological 
phenotypes in the VCPR155H/+ mouse model, in attempts to elucidate the possible cellular 
pathways that may be disrupted by VCP mutations.   
 An interesting feature of the disorder, observed by Badadani and colleagues 
(2010), was the presence of abnormal, swollen mitochondria in cryosections of quadriceps 
muscle obtained from aged knock-in VCPR155H/+ mice (Badadani et al., 2010). This may 
suggest a possible detrimental effect of VCP mutation on the energy metabolism of skeletal 
muscle. In recent years, the role of VCP in mitochondrial maintenance in cells has been 
investigated in depth. In 2006, researchers investigated mitochondrial function in a yeast 
model in which Cdc48, the VCP homolog in yeast, was mutated (Braun et al., 2006). 
Ultrastructural analysis of wild-type Cdc48 and Cdc48S565G yeast cells revealed abnormally 
large mitochondria in the mutant strain. Increased levels of cytosolic cytochrome c were 
observed in the Cdc48S565G cells, suggesting a possible decrease in mitochondrial membrane 
integrity in the mutant cells. The respiratory capacity of the Cdc48S565G cells was also 
compromised. A differential plating assay showed that the mutant cells were unable to 
proliferate on a lactate-rich medium, indicating an inability of these cells to utilise 
mitochondrial lactate oxidation to provide energy (Braun et al., 2006). The potential effects 
of mutant VCP expression on mitochondrial integrity and dynamics therefore warrant 
further investigation, as a reduction in the capacity of the mitochondrial network to 
generate the ATP could have profound effects on the survival of the cell. To that end, one 
of our primary aims was to investigate the effects of VCPR155H/+ expression on normal 
cellular function, specifically on the ability of skeletal muscle cells to contract and produce 
force. 
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1.5 Mitochondria - dynamics and degradation 
 Mitochondria are complex organelles, which form an interconnected tubular 
network under homeostatic conditions in the cell. This dynamic morphology is derived 
primarily from cyclical fission and fusion events between individual mitochondria and those 
in the network. The outer mitochondrial membrane (OMM) envelops the inner 
mitochondrial membrane (IMM) which contains the mitochondrial DNA in a protein-rich 
matrix. The IMM comprises numerous invaginations, or cristae, due to its large surface 
area, when compared to the OMM. These cristae are joined to the boundary 
intermembrane space (IMS) via thin tubular junctions. The highly flexible IMM and cristae 
undergo morphological changes when exposed to alterations in matrix volume and/or 
cellular metabolic state. Metabolic and apoptotic pathways are regulated, in part, by the 
mixing of biomolecular contents between the intra-cristae and IMS. The metabolic state of 
the mitochondrion itself also influences the conformation of the network (Heath-Engel and 
Shore, 2006).  
 The primary function of the mitochondrial network is to generate ATP. For this to 
occur, a proton gradient must be established between the membranous spaces inside the 
mitochondrion. The electron transport chain (ETC), comprised of a series of IMM protein 
complexes, shuttles electrons from electron donors to electron acceptors, via redox 
reactions. These reactions are coupled with the transfer of protons across the IMM to the 
IMS, which creates an electrochemical gradient. The gradient is used by the F0F1 ATP 
synthase complex to generate ATP via oxidative phosphorylation, as the chemiosmotic flow 
of H+ ions into the mitochondrial matrix from the IMS facilitates the phosphorylation of 
ADP by F0F1 ATP synthase. 
 Mitochondrial fusion helps to mitigate stress encountered by isolated 
mitochondria, by allowing the potentially damaging contents of the dysfunctional organelle 
to dissipate into the combined matrix of the mitochondrial network. Indeed, in cultured 
fibroblasts, the green fluorescent protein contained in a single mitochondrion was 
redistributed throughout the entire mitochondrial network in one hour, as a result of rapid 
fusion/fission events (Youle and van der Bliek, 2012). Fission events are required for the 
generation of new mitochondria, but also function in homeostatic ‘quality control’, by 
facilitating the extraction of terminally dysfunctional mitochondria from the network, thus 
preserving the integrity of the network (Heath-Engel and Shore, 2006). 
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 In mammalian cells, fusion and fission of mitochondria is facilitated by large 
guanosine triphosphatases (GTPases) from the dynamin family (collectively referred to as 
dynamin-related proteins, or DRPs), whose actions fuse and divide both the IMM and OMM 
(Ding et al., 2012). DRPs constitute a specialized subfamily of GTPases, which act as 
molecular motors to drive membrane remodelling (Escobar-Henriques and Anton, 2013). 
Mitofusins (Mfn) 1 and 2 are constitutively-expressed, OMM transmembrane GTPase 
proteins, which mediate the initial GTP-dependent mitochondrial docking/tethering events, 
when two mitochondrial tips or tubules are in close proximity to each other. Optic atrophy 
protein 1 (OPA1) is a key mediator of IMM fusion. Knock-out of Mfn1, or Mfn2, or OPA1 is 
embryonic-lethal (Chen et al., 2003; Davies et al., 2007). When Mfn2 is depleted after 
placental formation, mice exhibit impaired cerebral development, with a third of offspring 
dying at post-natal day 1 (Chen et al., 2007; Escobar-Henriques and Anton, 2013). Mice 
depleted of Mfn1 after placental formation are normal, indicating that only after this 
developmental stage, Mfn1, and not Mfn2, is dispensable (Chen et al., 2007). Mouse 
embryonic fibroblasts which lack both Mfn1 and Mfn2 or OPA1 (Chen et al., 2005) exhibit 
impaired mitochondrial membrane potential and respiratory capacity, highlighting the vital 
nature of mitochondrial fission and fusion for normal cellular and organism development 
and function.  
 The turnover of Mfn1 and Mfn2 is mediated by the ubiquitin/proteasome system 
(UPS).  In cell culture studies, proteasomal inhibition by MG132 was shown to stabilize both 
Mfn1 and Mfn2 and prevent their degradation. The reversible mitochondrial uncoupler, 
carbonyl cyanide m-chlorophenylhydrazone (CCCP), is routinely used to investigate 
mitochondrial dynamics. CCCP is a protonophore, and as such, causes rapid depolarization 
and fragmentation of mitochondria, by dissolving into the mitochondrial membrane and 
increasing its ionic permeability, specifically its permeability to H+. Exposure to this 
compound was shown to stimulate Parkin-dependent autophagic degradation of 
mitochondrial fusion proteins (Tanaka et al., 2010). PTEN (phosphatase and tensin 
homolog)-induced putative kinase 1, or PINK1, is an IMM-localised kinase involved in the 
initiation of mitophagy. Under homeostatic conditions, PINK1 is cyclically produced and 
cleaved, with the cleavage product being proteolytically degraded. When mitochondrial 
membrane potential is lost, PINK1 becomes stabilised and accumulates on the OMM. This 
acts as a signal to Parkin (Ashrafi et al., 2013). Parkin, a cytosolic E3-ubiquitin ligase 
encoded by the PARK2 gene, has been shown to translocate to functionally-impaired 
mitochondria. Upon translocation, the E3-ubiquitin ligase activity of Parkin increases,  
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which results in the increased ubiquitination of mitochondrial substrates, such as Mfn1, 
Mfn2 and VDAC1 (voltage-dependent anion-selective channel protein 1; Tanaka et al., 
2010; Narendra et al., 2008).  It has been suggested that both Parkin and PINK1 are 
involved in a common pathway which governs mitochondrial function and morphology, 
with PINK1 located upstream of Parkin. Interestingly, this pathway was negatively affected 
by the expression of an ATPase-deficient VCP mutant, VCPE305Q/E578Q (Tanaka et al., 2010).  
The E305Q mutation in the D1 domain and the E578Q mutation in the D2 domain result in 
a catalytically-dead VCP, however this double mutation is not seen clinically (Dalal et al., 
2004; Tresse et al., 2010, Watts et al. 2004). When HeLa cells transiently expressing the 
dominant negative ATPase-deficient VCPE305Q/E578Q mutant were treated with CCCP, Mfn1 
ubiquitination increased, yet its degradation via the PINK1-Parkin-mediated pathway was 
predominantly prevented (Tanaka et al., 2010), suggesting a key role of intact VCP in this 
pathway (Figure 1.5).  
 Most of the reported cellular roles of VCP involve recognition of and binding to 
(poly)ubiquitinated proteins, and either their segregation from associated binding partners 
or extraction from multiprotein complexes or membranes. It is possible therefore, that VCP 
may be acting as a segregase to remove these ubiquitinated mitochondrial proteins from 
the OMM, and that pathogenic VCP mutations impact on this function by preventing 
correct substrate binding, as evidenced by the build-up of ubiquitinated mitochondrial 
proteins (Tanaka et al., 2010). 
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Figure 1.5. Major pathways of mitochondrial quality control. (A) Dysfunctional 
mitochondrial proteins are selectively degraded via vesicular transport from the 
mitochondria to the lysosome. (B) When the mitochondrial membrane potential (ΨM) is 
lost in a single mitochondrion, they are selectively removed from the network by the 
degradation of OMM fusion proteins, facilitated, in part, by VCP as part of the UPS. PINK1 
becomes stabilised on the OMM upon dissipation of ΨM, and recruits cytosolic Parkin. 
Parkin-mediated hyper-ubiquitination of the OMM is recognised by p62 and other possible 
unidentified Ub-binding adaptors, which may be involved in the recruitment of the 
damaged mitochondria to the isolation membrane. This activity occurs through the 
interaction of these adaptors with LC3, an autophagosomal protein localised to the pre-
autophagosomal membrane (Adapted from Ashrafi et al., 2013). 
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 As the list of molecular functions of VCP continues to lengthen, it has become more 
important to clearly define the pathways in which cellular dysfunction occurs when 
mutated VCP is expressed. In vitro studies have provided further evidence of the role of 
VCP in mitochondrial maintenance.  Using a Drosophila model of VCP mutation, Kim and 
colleagues (2013) demonstrated that VCP recruitment to damaged mitochondria required 
Parkin-mediated ubiquitination of OMM proteins. As in the VCPR155H/+ mouse model, 
severely abnormal mitochondrial swelling and disorganisation (mitochondrial megaconia 
and pleioconia) were noted in the muscle tissue of VCP mutant flies. Indeed, VCP was 
shown to be essential in the degradation of mitochondrial membrane proteins and the 
clearance of dysfunctional mitochondria, as siRNA-mediated knock-down of VCP prevented 
the proteasomal degradation of Mfn1 and Mfn2 in HeLa cells stably expressing Parkin. This 
function of VCP was shown to be impaired when pathogenic VCP mutants were transiently 
overexpressed in the model, specifically the catalytically-dead VCP mutant, VCPE305Q/E578Q, 
or the clinically relevant VCPA232E mutant (Kim et al., 2013).  
 Further studies have identified the significance of functionally intact VCP in 
mitochondrial membrane protein homeostasis. Xu and colleagues (2011) showed that VCP 
is integrally involved in the extraction of ubiquitinated Mfn1, Mfn2 and Mcl1, an OMM-
associated anti-apoptotic protein, from the OMM, thus enabling their degradation by the 
proteasome. Again, this extraction process was inhibited when the ATPase activity of the 
protein was ablated, as evidenced by a build-up of ubiquitinated Mcl1. Of note, these 
experiments were conducted in HeLa cells, which do not endogenously express Parkin (Xu 
et al., 2011, Matsuda et al., 2010). This may provide evidence for a Parkin-independent role 
of VCP in mitochondrial maintenance. These observations are important in light of the 
pathogenesis of IBMPFD, as the tissues affected by the disease, such as skeletal muscle, do 
not express high levels of the Parkin protein. For this reason, the mechanism by which VCP 
mutation affects mitochondrial maintenance, in tissues with low Parkin expression (such as 
muscle), warrants further investigation, as it is in these tissues that the pathology presents 
in patients.  
 The observation of abnormal, swollen mitochondria in VCP disease models 
prompted researchers to investigate the potential effects of VCP mutation on 
mitochondrial membrane potential. Human fibroblasts isolated from patients carrying 
three different mutations in VCP; R155H, R155C and R191Q; showed decreased 
mitochondrial membrane potential.  Membrane potential-dependent mitochondrial uptake 
of tetramethylrhodamine methyl (TMRM) was reduced in these cells (Bartolome et al., 
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2013). The authors also reported significantly increased oxygen consumption in VCP-
mutated primary fibroblasts, compared with wild-type controls, however, ATP production 
was significantly decreased. These observations indicate that expression of a VCP mutant 
results in the uncoupling of oxidative phosphorylation and ATP generation.  
 Based on these studies, it is clear that our VCPR155H/+ knock-in mouse model could 
serve to further investigate potential effects of VCP mutation on mitochondrial 
maintenance and quality control. We focused our investigations on skeletal muscle tissue, 
to examine possible effects of VCP mutation on the ability of mitochondria to generate ATP 
for prolonged muscle contractile activity. Progressive muscle weakness is a symptom seen 
in both IBMPFD patients and knock-in VCPR155H/+ mutant mice, with respiratory failure due 
to muscle weakness being the main cause of death in patients. Forelimb muscle strength of 
wild-type and VCPR155H/+ mice has been compared, using grip strength testing (Nalbandian 
et al., 2012). Mouse forelimbs consist of muscles made up of numerous fibre types, 
therefore any differences in strength or contractile force seen in grip strength tests cannot 
be attributed to a specific muscle fibre type. Indeed, to our knowledge, fibre type-specific 
effects of VCP mutation on striated muscle function have not yet been investigated, 
therefore it important that the biomechanical and functional effects of VCP mutation are 
investigated in muscles composed of different fibre types.  
 One of the hallmark methods of mammalian skeletal muscle classification is based 
on myosin heavy chain (MHC) isoform expression. The main fibre types found in skeletal 
muscle are type I, IIA, IIX and IIB, and while all four MHC isoforms are found in rodent 
skeletal muscle, the MHC IIB isoform is not present in human muscle (Smerdu et al., 1994, 
Schiaffino et al., 2011, Westerblad et al.,, 2010). The rate of cross-bridge cycling, and thus 
the maximal shortening velocity, is determined by the MHC isoform expressed in a given 
muscle cell, with the slowest being type I, type IIA being classified as intermediate and IIX/B 
being the fastest (Westerblad et al., 2010). Faster MHC isoforms consume ATP at a higher 
rate than the slower subtype, therefore fibre type classification based on this parameter is 
relevant in the context of fatigue.  
 Fast/type II and slow/type I muscles differ in both mitochondrial content and the 
metabolic pathways used to generate ATP. The hydrolysis of ATP to ADP and inorganic 
phosphate (Pi) is the mechanism by which energy for all cellular functions, including 
skeletal muscle contractile activity, is derived. Skeletal muscle exhibits the unique ability to 
rapidly increase its energy consumption when switching from a resting state to one of high 
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contractile activity. In order to efficiently meet these dynamic energy demands, skeletal 
muscle has evolved mechanisms by which ATP can be resynthesized quickly (Schiaffino et 
al., 2011).  Fast and slow muscles rely on different ATP-generating pathways - glycolysis and 
oxidative phosphorylation, respectively. Oxidative mitochondrial processes generate nearly 
all of the ATP required for slow muscle contraction, while fast-twitch muscles primarily 
utilise anaerobic glycolytic processes for rapid ATP generation, which limits the duration of 
contractile activation due to the dependency upon intramuscular glycogen stores (Allen et 
al., 2008). One of the main determinants of fatigue resistance in skeletal muscle is 
mitochondrial content, and therefore oxidative capacity.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
37 
 
1.6 Aims and objectives: 
1.6.1 Aim 1: 
 We hypothesise that the fatigue tolerance of the VCPR155H/+ knock-in mouse muscle 
will be deficient when compared with WT controls. To test this hypothesis, we will 
characterise the biomechanical properties of different muscle fibre types in aged VCPR155H/+ 
and WT mice. We will subject fast- and slow-twitch muscle fibre bundles, isolated from 
age-matched WT and VCPR155H/+ mice, to an electrophysiological protocol, where contractile 
characteristics, specific force and fatigue tolerance will be assessed. This will further 
broaden our understanding of myopathic dysfunction in the IBMPFD disease model, as we 
will investigate the functional effects of VCPR155H/+ in two different muscle types, the fast-
twitch extensor digitorum longus (EDL) and the slow-twitch soleus, two muscles comprised 
of different fibre types.   
1.6.2 Aim 2: 
 Based on the observations of Badadani and colleagues, we hypothesise that 
mitochondrial degradation may be affected by VCPR155H/+ mutation. If the mutation does 
affect mitochondrial maintenance, the expression profiles of skeletal muscle fibre types 
may have adapted to utilise a different metabolic pathway for ATP generation. Therefore, 
we will examine the relative abundance of fibre types by immunostaining cryosections of 
muscle, to determine whether the expression of mutated VCP affects the distribution of 
different fibre types in skeletal muscle. We will also determine mitochondrial enzyme 
activity in VCPR155H/+ and WT age-matched muscle, to gain insight into the effect of 
VCPR155H/+ expression on mitochondrial respiratory activity. 
1.6.3 Aim 3: 
 Studies have demonstrated that VCP is required for the successful degradation of 
mitochondrial fusion proteins. We hypothesise that due to the presence of dysfunctional 
VCP in cells, the mitochondrial networks will not respond normally to exogenous stresses. 
Using tissues from our VCPR155H/+ mouse model, we will isolate and culture primary cells. 
We will examine the effects of oxidative stress on mitochondrial morphology, specifically 
on the ability of the network to effectively change its conformation, to adapt to such 
exogenous stresses. In addition, we will look at mitochondrial content in skeletal muscle, to 
determine whether VCPR155H/+ expression affects overall mitochondrial density in this tissue. 
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Chapter 2 
Materials and Methods 
 
2.1 VCPR155H/+ mouse model 
 The heterozygous VCPR155H/+ mutant mice used for protein analysis and muscle 
mechanic experiments were generated by Badadani and colleagues (2010). Using a FRT-
flanked Neomycin (Neo) cassette insertion, cultured 129/SvEv embryonic stem cells were 
modified to express the pathological VCPR155H/+ mutation, and injected into 129/SvEv 
blastocysts. The blastocysts were implanted in pseudopregnant females, and the chimeric 
offspring produced were mated with 129/SvEv mice, resulting in the F1 mutant generation. 
VCPR155H/+ mutant mice were back-crossed with mice of the C57BL/6 strain over six times, 
resulting in mice that retained >98% genetic homology with the C57BL/6 strain.  
 
2.1.1 Genotyping of VCP mice 
 A polymerase chain reaction (PCR) protocol was used to determine the mouse 
genotypes. For this, an ear punch or tail tip was taken from each mouse and placed in a 
sterile Eppendorf tube. The tissue was then digested using the HotSHOT alkaline lysis 
method (Truett et al., 2000). Briefly, 75µl of alkaline lysis reagent (25mM NaOH, 0.2mM 
disodium EDTA in ddH2O, pH 12) was added to the tissue sample and was heated to 95°C 
for 30-60 minutes. The tissue sample was checked at 30 minutes and the tubes agitated in 
order to estimate the degree of lysis. Once lysed, the tissue sample was cooled to 4°C and 
75µl of neutralisation buffer (40mM Tris-HCl in ddH2O, pH 5) was added. The samples were 
centrifuged at 775g for 3 minutes and the supernatant transferred to another sterile 
Eppendorf tube. The region encoding VCP in the genomic DNA template was amplified 
using ‘mus-vcp-genot-F’ and ‘mus-vcp-genot-R’ primers (sequences of these primers 
detailed in Table 2.1 and the PCR running conditions are listed in Table 2.2). 
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 To confirm the genotype, PCR products were digested with either restriction 
enzymes MspI (cuts WT allele) or NcoI (cuts mutant allele) restriction enzymes for 3 hours 
at 37°C. Fragments were separated on a 1% agarose gel at 120V for 1hour (Fig. S.1, 
supplementary data). 
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Table 2.1 List of oligonucleotides used  
Primers Sequence 
mus-gen-2F 5' - TGGAAGGCATCACTGGCAATCTCT 
mus-gen-2R 5' - TTAAGGCCATCCAATCTCCAAAAGTA 
 
 
 
Table 2.2 PCR running conditions 
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2.2 Ex vivo skeletal muscle biomechanics 
2.2.1 Muscle fibre bundle isolation 
 All animals used in biomechanics experiments were euthanized by cervical 
dislocation according to the Animals (Scientific Procedures) Act 1986, UK and all the 
experiments conformed to the local animal welfare committee guidelines. Hind limbs were 
removed and the EDL and soleus muscles were isolated and excised. Once excised, the 
muscles were gently stretched and pinned in place using surgical steel pins in a bath of 
Ringer’s solution containing 109mM NaCl, 5mM KCl, 1mM MgCl2, 4mM CaCl2, 24mM 
NaHCO3, 1mM NaHPO4, 10mM sodium pyruvate plus 200 mg/l foetal bovine serum (FBS). 
The majority of muscle fibres were then dissected away leaving approximately 6-10 intact 
muscle fibre bundles. The cross-sectional diameter (in µm) was recorded twice and 
averaged in order to calculate the specific force produced in each contraction. 
 
2.2.2 Muscle fibre fatigue protocol 
 The muscle fibre bundles were mounted horizontally in a stainless steel chamber 
between a force transducer and a motor using aluminium T clips attached to tendon. The 
chamber was constantly perfused with Ringer’s solution prepared as previously described 
and chamber was thermostatically maintained at 20°C using a thermocouple device. The 
sarcomere length (SL) was adjusted to give maximum tetanic tension (L0) using laser 
diffraction (SL ~ 2.5µm) (He-Ne laser; Laser Lines Ltd, Oxon, UK).   
 Fibre bundles were given 10-20 minutes to equilibrate in the chamber before the 
beginning of the fatigue protocol (FP). Maximum twitch and tetanic contractions were 
elicited as a control at a non-fatiguing stimulation rate of once every ninety seconds, and 
the rate was increased to once every nine seconds for EDL and once every four seconds for 
soleus during the FP. In fast-twitch fibre bundles, tetanic contractions were produced by 
applying the electrical stimulus at a frequency of 120 Hz for a duration of 100-150 
milliseconds, while in slow-twitch fibre bundles, a stimulation frequency of 30-40 Hz for 
500 milliseconds was required. Due to the fatigue-resistant nature of slow muscle fibres, a 
higher stimulation rate was used in the slow muscle fibre FP. The contraction stimulation 
rate was returned to once every ninety seconds when 65-75 contraction recordings had 
been made. Contractions were elicited at this rate for 10-15 minutes to allow the fibres to 
recover from the FP. Recovery was classified as a return to ≥90% P0 (control tension) within 
10-15 minutes. The force produced by the muscle fibre bundle and the temperature (from 
42 
 
the thermocouple) signals were collected via a CED 1401Micro laboratory interface using 
Signal 2.11 software (Cambridge Electronic Design Ltd, Cambridge, UK) and stored in a 
computer. The amplitude of the twitch and tetanus (in mN) was determined using the 
Signal 3.1 software.  
2.3 Mitochondrial respiration in skeletal muscle 
2.3.1 Citrate synthase assay 
 Buffers and reagents required for the assay were prepared as described in the 
product technical data sheet. Whole EDL muscles, which had been previously snap frozen 
in liquid nitrogen and stored at -80°, were homogenised using a TissueLyser LT 
homogeniser (Qiagen). All eppendorf tubes and homogenisation tungsten beads were 
precooled using dry ice. For the tissue preparation, Cellytic MT Cell Lysis Reagent (Sigma) 
supplemented with HALTTM Protease Inhibitor Cocktail (1:100 dilution, Sigma) was used in a 
ratio of 1 gram of tissue per 20mls of reagent. Each EDL was weighed and the appropriate 
volume of lysis reagent was calculated and added to a precooled eppendorf tube 
containing the EDL and a 5mm tungsten bead. The tissue was then homogenised at 50 Hz 
for 8-10 minutes. Next, the lysate was centrifuged at 14,000 RPM for 10 minutes and the 
supernatant collected into a fresh eppendorf tube, with 5µl aliquoted separately for BCA 
protein concentration analysis.   
 For the CS assay, an Omega (Model) spectrophotometric plate reader was set at 
412nm on a kinetic program, with absorbance being measured at 10 second intervals for 90 
second period. The assay solutions were warmed to 25°C before starting the reaction and 
aliquoted into the plate as per Table 2.3.  
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Table 2.3 Reaction scheme for citrate synthase assay in 96-well plate 
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 Initially, the absorbance of the reaction mixture was recorded for 90 seconds to 
measure baseline reaction, endogenous levels of thiol or deacetylase activity. 10µl of 
10mM OAA solution was added to each well using a multichannel pipette in order to 
initiate the reaction in each well simultaneously. The plate was shaken gently for 10 
seconds before the absorbance was recorded, again, once every 10 seconds for a total of 
90 seconds, to measure total CS activity. The absorbance values (A412) were plotted against 
time for each reaction, and the change in absorbance (ΔA412)/minute in the linear range of 
the plot was measured for endogenous activity and then for total activity (following the 
addition of 10mM OAA). The net CS activity was calculated by subtracting the 
(ΔA412)/minute of the endogenous activity from the (ΔA412)/minute of the total activity of 
the sample.  Citrate synthase activity (mmole/ml/min) then was calculated using the 
following equation:  
 
   {(ΔA412)/min x V(ml) x dil}/ εmM x L(cm) x Venz(ml) 
 
Where:  (ΔA412)/minute - net CS activity  
V(ml) – the reaction volume (0.2ml in 96 well plate) 
dil - the dilution factor of the original sample 
εmM - the extinction coefficient of TNB (13.6 at 412nm) 
L(cm) – the pathlength for absorbance measurement (0.552cm for 96 well plate) 
Venz(ml) – the volume of the enzyme sample in ml 
 
 
 The change in absorbance (ΔA412)/min was plotted for each sample (with 
duplicate experimental sample data being averaged at the final stages of the calculations) 
and the CS enzyme activity in EDL muscles from three WT mice was compared with that of 
three VCPR155H/+ mice using a two-tailed independent t-test to determine statistical 
differences. Despite n=3 for WT and VCPR155H/+ fast-twitch muscle samples from Group 3, a 
t-test is considered a valid test to compare the means of two groups if the effect size is 
expected to be large (de Winter, 2013). 
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2.4 Protein expression in WT and VCPR155H/+ knock-in mice 
 EDL muscle samples from WT and age-matched VCPR155H/+ knock in mice were snap 
frozen in liquid N2 and the total protein extracted using T-PER Tissue Protein Extraction 
Reagent (Thermo Scientific #78510) supplemented with HALTTM Protease Inhibitor Cocktail. 
Western blot analysis and the Odyssey Infrared Imaging System (Licor) were used to assess 
any differences in protein expression between the groups.  
2.4.1 Western blotting  
 Cells were lysed using M-PER Mammalian Protein Extraction Reagent (MPER) 
supplemented with HaltTM Protease Inhibitor Cocktail. Total protein concentration was 
determined by BCA assay (BCA Protein Assay Kit; Thermo Scientific Pierce, 23227) 
according to the manufacturers’ guidelines. For the SDS-PAGE, pre-cast 4-12% Bis-Tris 
(Novex, NP0335BOX) or 3-8% Tris-Acetate gels were used. Cell lysates were denatured by 
heating for 10 minutes at 70°C and then loaded into lanes at a volume equivalent to 15-
20µg/ml. Gels were run at 120 V constant for 1 hour. Proteins were then transferred onto 
nitrocellulose membranes using the XCell II Blot Module (Invitrogen, EI9051). Filter pads, 
Wattman filter paper, NC membrane and the gel were assembled into a ‘sandwich’, 
ensuring the gel was closest to the cathode component of the module. Proteins in the gel 
were transferred to the nitrocellulose membrane at 30 V constant for 1 hour. 
 The membrane was then washed in 1xPBS for 1 minute to remove residual transfer 
buffer followed by 1 hour in Odyssey Blocking Buffer (Licor) supplemented with 0.01% 
Tween. The membrane was then incubated with primary antibodies (Table 2.4) in blocking 
buffer for 1 hour at room temperature, or overnight at 4°C. Following 4 x 5 minute 1xTBST 
washes, the membrane was incubated with secondary antibodies (Table 2.6) diluted in 
blocking buffer for 1 hour. Finally, the membrane was washed as per previous and analysed 
using the Odyssey Infrared Imaging System (Licor). 
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2.5 Molecular Biology Methods 
2.5.1 Mammalian Cell Culture 
 Mouse embryonic fibroblasts (MEFs) were seeded in T75 flasks (Corning) at 2x105 
and cultured in Dulbecco’s Modified Eagles Medium (DMEM) with GlutaMAXTM (Invitrogen) 
supplemented with 10% HyClone heat-inactivated FBS (heated to 56°C for 30 minutes) and 
0.5units/ml Penicillin and 50µg/ml Streptomycin solution (complete growth medium).  
 Cells were propagated in a humidified incubator at 37°C with 5% CO2 until 
approximately 85-95% confluency was achieved, at which point cells were either passaged 
or subjected to a transfection protocol.  
 
2.5.2 Isolation and culture of primary murine skin-derived fibroblasts 
 Young mice (aged <6 months; n=3 for both WT and VCPR155H/+) were used for these 
experiments. Animals were sacrificed by cervical dislocation, and the abdomen of each 
mouse was sterilised with ethanol and the fur removed using a sterile razor blade. A skin 
biopsy of approximately 1.5cm2 was removed and dipped briefly in 70% ethanol, then in 
PBS. The biopsy was cut into smaller pieces in a petri dish using a sterile scalpel. In a 6-well 
plate, 3-4 smaller pieces of the biopsy were placed (skin side up) in each well and allowed 
10 minutes to dry in a 37°C incubator, to ensure the pieces adhered to the plate. 0.5ml of 
complete DMEM was added to each well and the plate was left for 3 days in a 37°C 
incubator with 5% CO2. After 3 days, fibroblast cells were observed proliferating outwards 
from the skin patch. At this stage, another 0.5mls complete DMEM was added to provide 
nutrients. After a further 2 days, the skin patches were removed and the media replaced 
completely. The fibroblasts were cultured until sufficient numbers were achieved for 
mitochondrial dynamics/further experiments to be carried out. 
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2.5.3 Preparation of Luria-Bertani (LB) Medium 
 In order to make 1 litre of Luria-Bertani or LB medium, 10g Bacto-tryptone, 5g 
Bacto-yeast extract and 10g of NaCl were dissolved in 900mls ddH2O in a sterile 1 litre 
storage bottle. When the additives were thoroughly dissolved, the pH was adjusted to 7.0 
by adding concentrated NaOH drop-wise and the volume was then made up to 1 litre by 
adding ddH2O. The solution was then sterilised by autoclaving at 120°C for 20 minutes. The 
medium was then allowed to cool and was stored at 4°C for no more than 3 months, at 
which point fresh medium was prepared. Antibiotics were freshly added to aliquots of LB 
medium as required.  
 
2.5.4 Isolation of plasmid DNA from bacterial cell culture 
 Following 18-24 hours incubation at 37°C, Falcon tubes containing 10mls LB broth 
supplemented with either 50mg/ml ampicillin or 50-100mg/ml kanamycin inoculated with 
DH5α Escherichia Coli (E. Coli) bacteria were centrifuged at 9000 rpm for 10 minutes at 4°C. 
The LB broth was aspirated off, with care taken not to disturb the bacterial pellet. A 
QIAprep Spin Miniprep Kit (QIAGEN, #27104) was used to isolate and purify the plasmid 
DNA according to the manufacturers’ protocol. Once the plasmid had been eluted in 
nuclease-free water, the DNA concentration was determined using an ultraviolet light 
spectrophotometer (NanoDrop ND-1000, Labtech).  
2.5.5 Transfection 
 MEFs were plated in a 12-well plate containing a sterile glass cover slip. The 
complete growth medium was removed and replaced by antibiotic-free DMEM 
supplemented with 10% heat-inactivated FCS for a minimum of four hours prior to 
transfection in order to allow the highest transfection efficacy possible. Plasmids purchased 
were EGFP-tagged WT-VCP and EGFP-tagged VCPR155H (plasmid maps of constructs in 
Supplementary data). The cells were transiently transfected with a complex of 1.6µg 
plasmid DNA and Lipofectamine 2000 transfection reagent (Invitrogen, #11668) in Opti-
MEMTM with GlutaMAXTM (Invitrogen) according to the manufacturer’s protocol. The cells 
were incubated for 24 hours at 37°C in order for protein biosynthesis to occur.  
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2.5.6 Immunostaining of transfected cells 
 Following the incubation period, the medium was aspirated from each well and the 
cells washed twice with warm PBS. A solution of 200nM MitoTrackerTM CMXRos (Molecular 
Probes, M-7512) was made using antibiotic-free DMEMTM and cells were incubated at 37°C 
in this solution in the dark for 30 minutes. The MitoTrackerTM CMXRos solution was then 
aspirated off and the cells washed in warm antibiotic-free DMEMTM for 5 minutes, followed 
by two PBS washes. Cells were then fixed in a 3.7–4% PFA solution for 20 minutes and 
washed several times using PBS. Cells were incubated with blocking buffer (PBS 
supplemented with 5% FCS and 0.01% Triton X) for 45 minutes at room temperature to 
block non-specific antibody binding. The cells were then incubated for either 1 hour at 
room temperature (RT) or overnight at 4°C on a shaking plate with primary antibodies 
(listed in Table 2.3) diluted in blocking buffer according to the product guidelines. Then 
cells were subjected to 4x5 minute washes with PBS-T (PBS with 0.1% Tween 20) and the 
secondary antibodies (listed in Table 2.4), also diluted in blocking buffer, were then added 
for 1 hour incubation at RT. Following 4xPBS-T washes, cover slips were mounted onto 
slides using approximately 20µL Vectashield with DAPI (Vector Laboratories). 
Immunofluorescence imaging was carried out using a Zeiss Imager M2 microscope with a 
CCD camera for fluorescence acquisition and images were processed using Axiovision 
Software (Version 4.8). 
 
 
 
 
 
 
 
 
 
 
 
49 
 
Table 2.4 List of primary antibodies used for immunofluorescence 
Antibody Company/code Reactivity Concentration Dilution 
Anti-VCP BD TL/612183 Mouse 250µg/ml 1/1000 
Anti-VCP Cell Signal/2648 Rabbit 9µg/ml 1/1000 
Anti-TOMM20 Sigma/HPA011562 Mouse 0.04mg/ml 1/1000 
Anti-TOMM20 Sigma/HPA011562 Rabbit 0.04mg/ml 1/1000 
Anti-actin Sigma/A3853 Mouse 1.8mg/ml 1/3300 
Anti-Parkin Abcam/15954 Rabbit 1mg/ml 1/1000 
Anti-Mfn2 Sigma/M6319 Rabbit ~1mg/ml 1/1000 
Anti-MHCIIA Novacastra Mouse Not available 1/5 
Anti-MHCIIB Novacastra Mouse Not available 1/5 
Anti-Nidogen-1 In-house (Mayer lab) Rabbit Serum 1/2000 
Anti-COX-IV Abcam/ab14744 Rabbit 0.04mg/ml 1/1000 
Anti-MHCf Novacastra Mouse Not available 1/10 
Anti-MHCs Novacastra Mouse Not available 1/10 
 
 
 
Table 2.5 List of secondary antibodies used for immunofluorescence 
Antibody  Company/Code Reactivity Concentration Dilution 
Chicken Alexa 
Fluor 594  
Mol Prob /A-21201 Mouse 2 mg/ml 1/1000 
Chicken Alexa 
Fluor 594  
Mol Prob/A-21442 Rabbit 2 mg/ml 1/1000 
Chicken Alexa 
Fluor 488  
Mol Prob/A-21200 Mouse 2 mg/ml 1/1000 
Chicken Alexa 
Fluor 488  
Mol Prob/A-21441 Rabbit 2 mg/ml 1/1000 
Goat Alexa Fluor 
350  
Mol Prob/A-11045 Mouse 2 mg/ml 1/1000 
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Table 2.6 List of secondary antibodies used for Western blotting (Odyssey Infrared 
Imaging System compatible) 
Antibody Company/code Reactivity Concentration Dilution 
Goat anti-rabbit 
IRDye 680LT 
Licor/926-32221 Rabbit 0.5mg/ml 1/10000 
Goat anti-mouse 
IRDye 680LT 
Licor/926-32220 Mouse 0.5mg/ml 1/10000 
Goat anti-rabbit 
IRDye 800CW 
Licor/926-32211 Rabbit 0.5mg/ml 1/10000 
Goat anti-mouse 
IRDye 800CW 
Licor/926-32210 Mouse 0.5mg/ml 1/10000 
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2.5.7 Immunostaining of mouse hind limb cryosections 
 After mice were sacrificed via CO2 inhalation, hind limbs were removed at mid-
femur level and frozen in isopentane cooled with liquid nitrogen. The limbs were stored at -
80°C until further use. For sectioning, the limbs were mounted vertically onto a cryostat 
chuck using OCT medium. 10µm thin cryosections were cut from the limbs and placed onto 
polylysine coated microscope slides. Slides were stored at -20°C for a maximum of 3 days 
before immunostaining. Sections were rehydrated in PBS for 10 minutes. They were then 
fixed with 1% PFA in PBS for 10 minutes at RT in a humidity chamber. Three washes of PBS 
+ 0.1% Tween-20 (PBS-T) for 5 minutes were performed.  
 Slides were permeabilized in methanol at -20°C for 8 minutes and then washed 
three times in PBS-T for 5 minutes.  Non-specific binding was blocked using 5% FCS in PBS-T 
for 90 minutes at 37°C in a humidity chamber. Sections were then briefly rinsed with PBS-T.  
1° and 2° antibodies were prepared by centrifuging at 13,000rpm for 5 minutes before use, 
then diluting in 2% FCS in PBS-T according to optimum working concentration (Table 2.4 
and 2.5). Sections were incubated with 1° antibodies for 1 hour at 37°C in a humidity 
chamber. Sections were washed three times in PBS-T for 5 minutes at RT, and then 
incubated with 2° antibodies for 1 hour at RT in a humidity chamber.  
 After 2° antibody incubation, slides were washed twice with PBS-T for 5 minutes, 
followed by one 5 minute wash in PBS. Sections were then mounted with gelvatol (in-
house) and stored in the dark at 4°C to set, until further analysis. The sections were labelled 
according to the mouse identification number they were taken from, therefore the 
investigators were blinded to the genotype until after the images had been analysed. 
 
2.6 Data analysis 
 Data was analysed using a two-way ANOVA with Tukey post-hoc analysis, an 
unpaired student’s t-test or a Mann-Whitney test of ranks. Significance was recorded when 
the resulting p-value was ≤0.05. A two-way ANOVA, also called two-factor ANOVA, 
determines how a response is affected by two factors, for example, genotype and stress 
condition. The unpaired t-test compares the means of two unmatched groups and the 
Mann-Whitney test of ranks is a nonparametric test comparing the distributions of two 
unmatched groups. 
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Chapter 3: Expression of VCPR155H/+ 
decreases fatigue tolerance and 
increases post-fatigue recovery 
time in a fibre type-specific manner 
3.1 Introduction 
 
 Mammalian skeletal muscle is a highly heterogeneous tissue. Its diversity stems 
from the numerous fibre types it is comprised of, which are metabolically suited to a wide 
range of functional requirements. During exercise, ATP is utilised by three different 
ATPases in skeletal muscle for contraction to occur. The sodium/potassium (Na+/K+)-ATPase 
pumps sodium ions out of and potassium into the muscle fibre following an action 
potential. ATP is also used by the myosin ATPase to generate mechanical force during 
cross-bridge cycling. The calcium (Ca2+) ATPase is responsible for pumping cytosolic calcium 
back into the sarcoplasmic reticulum to facilitate muscle relaxation. Each of these ATPases, 
contributes 10, 60 and , 30% of total skeletal muscle ATP use, respectively (Homsher, 
1987). Fast-twitch muscle fibres rely primarily on glycolysis to rapidly generate ATP for 
contraction, with longer term energy production facilitated by oxidative phosphorylation in 
the mitochondria (Schiaffino and Reggiani, 2011). If mitochondria in fast-twitch fibres are 
dysfunctional, the reduced capacity of the mitochondrial network to produce ATP for long 
term contractile activity would negatively affect the ability of fast fibres to resist fatigue.  
 We therefore hypothesised that possible pathogenic effects of VCPR155H/+ mutation 
on skeletal muscle fatigue tolerance would be seen to a greater extent in fast-twitch 
glycolytic fibres as they contain fewer mitochondria, therefore rely more heavily on a fully 
functioning mitochondrial network for ATP generation for longer-term contractile activity. 
To that end, slow-twitch fibres would not be affected to the same degree by the VCPR155H/+ 
mutation as they have a higher mitochondrial content, therefore the proposed detrimental 
effects of mitochondrial dysfunction on fatigue tolerance would be diluted into the larger 
mitochondrial network.  
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 We conducted biomechanical experiments to examine the contractile properties of 
isolated muscle fibre bundles from the soleus and extensor digitorum longus (EDL) muscles. 
The myopathic effects of VCP mutation in IBMPFD patients have been well documented, 
however to our knowledge, fibre type specificity has not yet been investigated. In order to 
assess the functional consequences of mutated VCP expression, we conducted muscle 
mechanics experiments on fast- and slow-twitch muscle fibre bundles excised from age-
matched VCPR155H/+ mutant and wild type (WT) mice. We compared the rate and extent of 
force decline in fibre bundles during a fatiguing protocol. Fatigue is defined as the 
reversible decline in contractile force associated with continuous activity of muscle (Allen 
et al., 2008). In order to determine whether the effects of VCP mutation, if any, were fibre 
type-specific, we used muscle fibre bundles dissected from the EDL and soleus. Skeletal 
muscle is a highly metabolically heterogeneous tissue (Pette, 1985), therefore it was 
important to select muscles which were classified as predominantly fast- or slow-twitch. 
The EDL muscle consists of MHC type IID/X (approx. 30%) and IIB (approx. 66%) fibres 
making this a glycolytic or fast-twitch muscle (Augusto et al., 2004), which is metabolically 
suited to short bursts of rapid contractile activity and susceptible to fatigue. Therefore, a 
degree of fatigue in the EDL muscle fibre bundles was predicted upon exposure to a fatigue 
protocol. The soleus is a mixed muscle that is comprised mainly of oxidative fibres with 
fibre types I (approx. 40 %) and IIA (approx. 55%) present (Augusto et al., 2004), thus 
making it more fatigue-resistant compared with the EDL. 
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3.2 Results 
 As the pathophysiological effects of VCP mutation are age-dependent, we chose to 
investigate potential biomechanical alterations in a cohort of animals divided into four age 
groups, as outlined in Table 3.1. Our preliminary muscle mechanics data indicated that, in 
accordance with the known age-dependent development of myopathy  in IBMPFD, 
decrements in force production were observed in fast-twitch muscle fibre bundles from 
VCPR155H/+ animals aged 350 days onwards. For this reason, we chose two age groups which 
were quite close together (Groups 2 and 3), in order to pinpoint the age at which the 
changes were seen to occur. We also chose an age range considered extremely aged (Group 
4) in the context of the C57BL/6 mouse lifespan, as the average lifespan of this strain ranges 
from 827±14.4 days in males and 818±21.0 days in females (Goodrick et al., 1975). We 
tested at least four fast and four slow muscle fibre bundles from each age-group in order to 
generate a comprehensive picture of the anticipated myopathic alterations. The data from 
the muscle mechanic experiments were compared statistically using an ANOVA and the 
results are represented graphically (Figures 3.1(A-E)-3.4(A-E)).  
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Table 3.1. Age groups of mice used in experiments. 
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3.2.1. Neither fast- nor slow-twitch muscle specific force is affected 
by VCPR155H/+ expression in any age group 
 We devised a minimal fatigue protocol (FP) in which muscle fibre bundles were 
initially allowed to equilibrate in the test chamber whilst being stimulated maximally for a 
pulse train of 100ms every 90 seconds pre-FP. For the FP, we elicited maximal isometric 
contractions at a rate of 1 stimulus every 9 seconds for fast-twitch fibre bundles and 1 
every 4 seconds for slow-twitch bundles, for a total of 60 contractions. The stimulation rate 
was returned to 1 every 90 seconds for a period of 12-15 minutes to allow fibre bundles to 
recover to pre-FP force production (P0). The rate and degree of fatigue was assessed using 
Signal 3.1 software. 
Absolute specific force (as calculated by dividing the force produced, in mN, by the fibre 
bundle’s cross-sectional area in µm2) was recorded at specified contractions during the 
fatigue protocol and the collated data from at least four WT and VCPR155H/+ fibre bundles in 
each age group were averaged (Figure 3.1 and 3.2). No significant differences were 
observed in absolute specific force between WT and VCPR155H/+ fast- and slow-twitch fibres 
in any age group (Figures 3.1 and 3.2, respectively).  
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Figure 3.1 Comparison of rate and degree of fatigue of fast-twitch muscle fibre bundles 
from age-matched WT and VCPR155H/+ mice. Averaged specific force generated by age-
matched WT and VCPR155H/+ fast-twitch muscle fibre bundles isolated from EDL. Contraction 
number is indicated on the x-axis. The vertical dashed line at contraction 60 indicates the 
end of the fatigue protocol and the beginning of the recovery period, where the 
stimulation frequency was returned to the pre-FP rate of  1/90sec. Note, in 14 months 
(Group 3), only 25% of VCPR155H/+ fast-twitch fibre bundles used recovered to produce a 
contraction force of ≥90% of P0 following the fatigue protocol (the inclusion criteria for 
healthy, live fibre bundles), therefore C represents the FP force data from the VCPR155H/+ 
fast-twitch fibres which  recovered post-FP and D represents the pooled FP data from all 
VCPR155H/+ fibres tested in this group including those which did not recover post-FP (n=12 in 
total). Solid squares represent WT and open circles represent VCPR155H/+ data ±SEM. (Note: 
graphs represent data from at least 3 different mice for each condition; n≥3 fibre bundles 
for each condition). Asterisk indicates significance of p<0.05. 
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Figure 3.2 No significant differences observed in fatigue profiles of slow-twitch fibre 
bundles from WT and VCPR155H/+ in any age group. Graphic representation of the rates of 
decrease in actual specific force in kN/m2 of age-matched WT and VCPR155H/+ slow-twitch 
fibre bundles during the fatigue protocol. Interestingly, at 12 months (Group 2) and 
27months (Group 4) the slow-twitch fibre bundles produced greater specific force than 
age-matched WT fibre bundles. Values represent averaged specific force at the indicated 
contractions of the fatigue protocol  ±SEM. Solid squares represent WT and open circles 
represent VCPR155H/+ data (Note: graphs represent data from at least 3 different mice for 
each condition; n≥3 fibre bundles for each condition).  
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3.2.2. Effects of VCPR155H/+ mutation on normalised specific force are 
age- and fibre type-specific 
 Due to the relatively high variation in standard error in actual specific force, we 
normalised specific force to the initial contraction of the FP, P0. Significant differences in 
the rate and degree of fatigue between WT and VCPR155H/+ muscle were revealed when 
absolute specific force was normalised to P0. Fast-twitch fibres from 12 month old (Group 
2) VCPR155H/+ EDL fatigued to a greater extent than WT controls, with significantly lower 
normalised force produced by these fibres from contraction 40 onwards (Figure 3.3, B). A 
dramatic functional change in fatigue characteristics of 14 months old VCPR155H/+ fast-twitch 
fibres was observed (Figure 3.3, C and D). Here, 75% of VCPR155H/+ fast-twitch fibres tested 
did not recover to ≥90% of P0 within the given post-FP recovery period of 15 minutes. 
Usually, any fibres that did not recover at least 90% of their initial contraction force would 
not be included in the analysis, but due to the high number of ‘non-recovering’ fibres in this 
group, these data points were included. A significant loss of fatigue resistance, from 
tetanus 40 onward, was seen in this age group (Figure 3.3, C). This high rate of attrition was 
not observed in any other age group, suggesting that this high proportion of non-
recovering fibres and the loss of fatigue tolerance are due to a functional effect of 
VCPR155H/+ mutation rather than possible fibre injury during isolation and subsequent death 
in the chamber. If the values of these non-recovering fibres are removed from the analysis, 
the only significant difference between WT and VCPR155H/+ fast-twitch fibres is in the post-FP 
recovery rate. The fatigue resistance is unaffected (Figure 3.3, C).   
 In Group 5 (Figure 3.3, E), comprising the oldest mice used in these experiments 
(27 months of age), no significant differences were observed between the fatigue 
characteristics of VCPR155H/+ mutant and control fast-twitch fibre bundles. Although not 
statistically significant, at 27 months of age the VCPR155H/+ fast-twitch fibres appeared to 
recover slightly better than WT control fibres (Figure 3.3, E). The fatigue tolerance of slow-
twitch fibres was not significantly different between WT control and VCPR155H/+ mutant 
fibres in any age group (Figure 3.4, A-D). At 14 months of age, the VCPR155H/+ slow-twitch 
fibres appeared to fatigue to a greater extent than WT controls, however this was not 
statistically significant (Figure 3.4, C). These results are summarised in Figures 3.5A and B, 
showing the average peak force produced by the last contraction (C60) in the fatigue 
protocol for all age groups. 
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Figure 3.3 VCPR155H/+ mutation results in an age-specific  decrease in fatigue tolerance in fast-
twitch VCPR155H/+ fibres when compared with wild type controls. Averaged normalised specific 
force (P/P0) was plotted at specified points during the fatigue protocol (FP) for each age group. 
The dashed line represents contraction 60, the final contraction of the FP and the beginning of 
the 12-15minute post-FP recovery period. At 6 months (Group 1), both WT and VCPR155H/+ fast-
twitch fibre bundles fatigue similarly and recover to the same degree following the FP. 
However, at 12 months (B, Group 2), VCPR155H/+ fast-twitch fibres exhibit fatigue intolerance, 
evidenced by a significant reduction in normalised specific force compared with WT controls 
from contraction 40 onwards. As before, at 14 months (Group 3; C and D), only 25% of 
VCPR155H/+ fast-twitch fibre bundles recovered to produce contraction force of ≥90% of P0 
following the fatigue protocol (the inclusion criteria for healthy, live fibre bundles), therefore C 
represents the fatigue data from the VCPR155H/+ fast-twitch fibres which  recovered post-FP and 
D represents the pooled fatigue data from all VCPR155H/+ fibres tested in this group including 
those which did not recover post-FP (n=12 in total). Solid squares represent WT and open 
circles represent VCPR155H/+ data ±SEM. Asterisk (*) indicates significance of p<0.05, ** indicates 
p<0.005. (Note: graphs represent data from at least 3 different mice for each condition; n≥3 
fibre bundles for each condition). 
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Figure 3.4 No significant differences found between WT and VCPR155H/+ normalised slow-
twitch fibre bundle specific force data in any age group. Specific force data from slow-
twitch fibre bundles isolated from solei of age-matched WT and VCPR155H/+ mice and 
subjected to the fatigue protocol was normalised (P/P0). Statistical analyses did not reveal 
any significant differences between WT and VCPR155H/+ slow-twitch fibre bundles in terms of 
rate of fatigue or recovery time post-FP in any age group (Note: graphs represent data from 
at least 3 different mice for each condition; n≥3 fibre bundles for each condition). 
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Figure 3.5 Significant decline in force production by fast-twitch fibre bundles from 12 and 
14month old (Groups 2 and 3) VCPR155H/+ mice during fatigue protocol. Graphs represent 
the decrease in force produced by fast-twitch (A) and slow-twitch (B) fibre bundles across 
all age groups at the final contraction of the fatigue protocol (P60/P0). (A) Averaged 
normalised specific force data at contraction 60 (end-FP) shows the significant decrease in 
force produced by VCPR155H/+ fast-twitch fibre bundles at 12 and 14 months when compared 
with WT controls. (B) Slow-twitch fibre bundles from VCPR155H/+ performed similarly to WT 
age-matched controls in all groups, suggesting that the fatigue intolerance observed is 
unique to fast-twitch muscles. 
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3.2.3. Post-FP recovery to P0 is significantly longer in fast-twitch 
muscle fibre bundles from VCPR155H/+ at specific ages 
 After the end of the fatigue protocol, the stimulation rate was returned to the pre-
FP rate of 1 every 90 seconds and the fibres were allowed to recover until their peak force 
reached ≥90% of P0. At 6 months of age (Group 1), there were no significant differences in 
the peak force (Figure 3.1, A) or the post-FP recovery time (Figure 3.6, A) of wild-type and 
VCPR155H/+ fast-twitch fibres. This was to be expected as there were no significant 
differences in the rate or degree of fatigue of these fibres either (Figure 3.1, A).  At 14 
months (Group 3), there was a loss of fatigue resistance (Figure 3.3, C and D) and the peak 
tetanic contraction force generated during the recovery period remained significantly 
lower than WT for most of the recovery period (Figure 3.6, C). This shift towards a 
lengthening of the average recovery time for VCPR155H/+ fast-twitch fibre bundles at this age 
is shown in Figure 3.6 E. Again, it should be noted that for Group 3, the VCPR155H/+ data 
represent only the fibres that recovered to ≥90% of P0 post-FP.  
 At 27 months of age (Group 4), in a manner similar to the fatigue protocol results, 
there was no significant difference between WT and VCPR155H/+ in terms of the rate of 
recovery to ≥90% P0 (Figure 3.6D) or average recovery time (Figure 3.6E). Slow-twitch fibre 
bundles from the soleus did not show any differences in average specific force (Figure 3.2, 
A-D), average normalised force (Figure 3.4, A-D) or post-FP recovery time (Figure 3.7, A-D).  
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Figure 3.6 Fast-twitch fibre recovery from fatigue was significantly delayed in aged 
mutant mouse. Average normalised force (P/P0) following fatigue protocol. Simulation rate 
was returned to the pre-FP non-fatiguing rate of once every 90 seconds and fibres were 
given 12-15 minutes to recover force. At 6 months (Group 1) WT and VCPR155H/+ fast-twitch 
fibre bundles recover at the same rate post-FP. At 1 year, there is a small but significant 
delay in VCPR155H/+ fibre recovery compared with WT (B). This effect becomes more 
pronounced at 14 months (C), with recovery to ≥90% P0 significantly delayed and 
normalised force significantly lower than WT. Interestingly, this pathology was not 
observed in fast-twitch fibre bundles from very aged mice (27 months; Group 4); WT and 
VCPR155H/+ fast-twitch fibres recover from the FP similarly, with a higher average normalised 
force produced by VCPR155H/+ fast-twitch fibre bundles at this age (D). The averaged fast-
twitch fibre post-FP recovery times for each group are collated in E, with VCPR155H/+ fibres 
taking significantly longer to recover force post-FP at 14 months when compared with WT 
controls (* indicates p <0.05, # indicates p<0.01, ** indicates p<0.001) (Note: graphs 
represent data from at least 3 different mice for each condition; n≥3 fibre bundles for each 
condition). 
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Figure 3.7 No difference in rate of post-FP recovery of slow-twitch fibre bundles from 
VCPR155H/+ mice in any age group. Average normalised force (P/P0) produced by age-
matched WT and VCPR155H/+ slow-twitch fibre bundles following the fatigue protocol. 
Simulation rate was returned to the pre-FP non-fatiguing rate of 1/90seconds and fibres 
were stimulated at this rate for 12-15 minutes to allow force recovery as for fast-twitch 
fibre bundles. No significant differences were observed in the average rate of recovery 
between WT and VCPR155H/+ slow-twitch fibre bundles in any age group, suggesting that the 
impaired post-FP recovery is an age-specific characteristic of fast-twitch fibres from 
VCPR155H/+ mice. 
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3.2.4. Analysis of fibre type distribution in fast-twitch muscles from 
12 and 14 month old WT and VCPR155H/+ mice 
 As previously outlined, the EDL muscle is categorised as a fast-twitch muscle 
capable of short contractile bursts before exhibiting fatigue. This categorisation is largely 
due to the primary energy metabolism of fast-twitch skeletal muscle (Allen et al., 2008).  
Large differences exist between skeletal muscle fibre types regarding their glycolytic versus 
oxidative capacity, such as resistance to fatigue or speed of contraction.  
 With this in mind, it was important for us to determine the oxidative versus 
glycolytic fibre ratio in fast-twitch muscles from age-matched WT and VCPR155H/+ mice, 
based on our observations of fibre type-specific age-dependent fatigue intolerance. We 
chose to examine the fibre type composition of fast-twitch muscles of mice aged 12 and 14 
months, deemed the ‘critical ages’ for the onset of VCP-related myopathic dysfunction. To 
do this, we sectioned cryopreserved mouse hind limbs into 10µm thick slices using a 
microtome. These sections were immunostained, using either a monoclonal antibody 
raised against MHC-IIB, to identify fast glycolytic fibres, or a rabbit polyclonal antibody 
against cytochrome c oxidase subunit IV (COX-IV), to identify fast oxidative fibres. COX-IV is 
one of the 13 subunits of cytochrome c oxidase, which is the terminal complex in the 
electron transport chain (ETC) in mitochondria (Li et al., 2006).  
 In order to demarcate the basement membrane for analysis of the fibre area, we 
used a rabbit anti-Nidogen-1 antibody in conjunction with the mouse anti-MHC-IIB 
antibody. We proceeded to image the entire EDL muscle and used ImageJ software to 
assign a unique number to each fibre based on the red channel (Nidogen-1 stain). Fibres 
were visually recorded as MHC-IIB-positive when strong staining was observed. In some 
sections, where part of the tissue had been damaged by the blade or the slice had partially 
folded back on itself, only fully visible fibres were included in the analysis. In order to 
identify fast-oxidative fibres, the corresponding fibres on COX-IV-immunostained serial 
sections were found and categorised as fast-oxidative when strong COX-IV staining was 
seen. Fibres were classified as intermediate (fast-oxidative glycolytic) when faint COX-IV 
and MHC-IIB staining was observed in the same fibre in serial sections. The relative 
abundance of fibre types in EDL from 12 and 14 month old WT and VCPR155H/+ mice was 
determined and expressed as a ratio of the total number of fibres analysed per EDL (Figure 
3.8 B and 3.9 B, respectively).  
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 No significant differences were found in the relative frequency of each fibre type 
between WT and VCPR155H/+ at 12 or 14 months of age (Figures 3.8 B and 3.9 B, 
respectively). At 14 months of age, VCPR155H/+ EDL was comprised of 57.6±4.2% fast-
glycolytic fibres compared with 49.2±1.8% in WT EDL. This difference in fibre type 
distribution however was not statistically significant. Based on COX-IV immunostaining, 
VCPR155H/+ EDL contained 35.2±8.3% fast-oxidative fibres, with WT EDL containing 
45.3±3.4%. Intermediate fibres, which co-stained for both COX-IV and MHC-IIB, made up 
5.5±1.9% of total EDL muscle area in WT and 7.3±4.1% in VCPR155H/+. A slight shift towards a 
more glycolytic fibre type in VCPR155H/+ mice is seen at 14 months of age when compared 
with WT, however this is not significant when compared statistically.  
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Figure 3.8 Fibre type distribution in EDL in WT and VCPR155H/+ mice is not significantly 
different at 12 months of age. (A) Fast glycolytic, fast oxidative and intermediate fast 
oxidative-glycolytic fibres were identified by immunostaining 10µm thick cryosections of 
whole hind limbs from Group 2 WT (left) and VCPR155H/+ (right) mice with antibodies against 
MHC-IIB and the mitochondria-specific protein COX-IV (A; scale bar = 100um). Fibres were 
classified as fast glycolytic when strong MHC-IIB staining was observed (asterisk); fast 
oxidative when strong COX-IV staining was seen (white arrow) and intermediate when both 
stains were observed in the same fibre (white arrow head) (B) ImageJ software was used to 
analyse the area of EDL fibres (average fibres counted per EDL: 684) and no significant 
differences were found in fibre type composition between WT and VCPR155H/+ mutant mice 
at 12 months of age. (Three different animals were used for both WT and VCPR155H/+). 
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Figure 3.9 Fibre type distribution in EDL in WT and VCPR155H/+ mutant mice is not 
significantly different at 14 months of age. (A) Fast glycolytic, fast oxidative and 
intermediate fast oxidative-glycolytic fibres were identified by immunostaining 10µm thick 
cryosections of whole hind limbs from Group 3 WT and VCP mice with antibodies against 
MHC-IIB and the mitochondria-specific protein COX-IV (A; scale bar = 100µm). An anti-
nidogen antibody was used to identify the basement membrane around each fibre. Fibres 
were classified as fast glycolytic when strong MHC-IIB staining was observed (asterisk); fast 
oxidative when strong COX-IV staining was seen (white arrow) and intermediate when both 
stains were observed in the same fibre (white arrow head) (B) ImageJ software was used to 
analyse the area of EDL fibres (average fibres counted per EDL: 643) and no significant 
difference was found in the frequency of the three fibre types between WT and VCP 
mutant mice at 14 months of age. 
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3.2.5 Significant differences found in fibre size in 12 and 14 month 
old VCPR155H/+mice when compared with WT control 
 After designating fibres types in EDL and finding no significant differences in the 
ratio of the three fibre types between WT and VCPR155H/+ mice at 12 and 14 months, we 
next chose to investigate whether the sizes of each fibre type in EDL were different 
between the two genotypes. This would give a more comprehensive picture of the total 
space occupied by each fibre type in the muscle. An inverse relationship exists between 
fibre thickness and aerobic oxidative capacity/mitochondrial content (Schiaffino and 
Reggiani, 2011).  
 We compared the distribution of sizes of COX-IV positive fibres in WT and VCPR155H/+ 
EDL from 12 (Group 2) and 14 (Group 3) month old mice and identified significant 
differences in the areas of specific fibre types (Figure 3.10). At 12 months, EDL muscle from 
VCPR155H/+ mice contained significantly larger COX-IV/fast-oxidative fibres and MHC-IIB/fast-
glycolytic fibres than those in WT controls (Mann-Whitney comparison, p < 0.0001). At 14 
months (Group 3), the COX-IV-positive and intermediate fibres in VCPR155H/+ were 
significantly larger than those in age-matched WT EDL (Mann-Whitney test, p<0.0001). 
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Figure 3.10 Differences between areas of specific fibre types in EDL from age-matched 
WT and VCPR155H/+. Serial cryosections of EDL were immunostained in order to determine 
fibre type and oxidative capacity. Fibre types were assigned manually based on 
immunostaining, with fibres being classified as fast glycolytic when strong MHC-IIB staining 
was observed ; fast oxidative when strong COX-IV staining was seen and intermediate when 
both stains were observed in the same fibre. An anti-Nidogen antibody stained the 
basement membrane and ImageJ software was used to analyse fibre area (in µm2) based 
on the Nidogen stain. The range of areas from three WT and three VCPR155H/+ EDLs was 
compared using a Mann-Whitney test. At 1 year (Group 2), both COX-IV-positive and MHC-
IIB-positive fibres were significantly larger in VCPR155H/+ EDL (p<0.0001 in both fibre types). 
The range of areas of intermediate or fast-oxidative-glycolytic fibres was not significantly 
different at 1 year of age between WT and VCPR155H/+ EDL. At 14 months (Group 3), the 
COX-IV-positive and intermediate fibres in VCPR155H/+ were significantly larger than those in 
age-matched WT EDL (n=3 for both; p<0.0001). Solid squares represent WT mean values 
±SD and open circles represent VCPR155H/+ ±SD. 
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3.2.6 Analysis of oxidative capacity and mitochondrial content of 
fast-twitch muscles from age-matched WT and VCPR155H/+ mice  
 The next logical step in our analysis of the metabolic profiles of fast-twitch muscle 
from VCPR155H/+ mice was to examine some of the biochemical properties of the tissue. 
Citrate synthase (CS) is a key regulatory enzyme which catalyses the primary step of the 
tricarboxylic acid (TCA) cycle – the condensation reaction between acetyl coenzyme A 
(acetyl CoA) and the four-carbon oxaloacetate (OAA) - resulting in the formation of six-
carbon citric acid or citrate (Lyons et al., 2002). The enzyme itself is located within the 
mitochondrial matrix. CS activity is routinely used as a semi-quantitative marker of 
oxidative and respiratory capacity and mitochondrial content (Stump et al., 2003, Delp et 
al., 1996, Lyons et al., 2006), therefore we chose to investigate whether the enzyme 
activity of CS in fast-twitch muscles was altered as a consequence of VCPR155H/+ expression. 
As with the fibre type distribution analysis, we chose to focus our investigations on the age 
groups in which fatigue intolerance was observed in the biomechanics experiments, i.e 
Group 2 (12 months) and Group 3 (14 months).  
The assay is based on the CS-catalysed reaction between acetyl CoA and OAA, whereby two 
carbons are contributed by acetyl CoA to the four carbon OAA, resulting in a six-carbon 
citrate.  
Acetyl CoA + Oxaloacetate → Citrate  + CoA-SH + H+ + H20 
The hydrolysis of the thioester of acetyl CoA results in the addition of a thiol group to acetyl 
CoA (CoA-SH). This thiol group reacts with 5,5'-dithiobis-2-nitrobenzoic acid (DTNB) in the 
reaction mixture to form the yellow product 5-thio-2nitrobenzoic acid (TNB). The 
absorbance of TNB is measured spectrophotometrically at 412nm and is an indicator of 
CoA-SH production (Sigma Aldrich product information sheet).  
CoA-SH + DTNB → TNB + CoA-S-S-TNB 
After recording endogenous thiol and deacetylase activity over an 80 second period, we 
initiated the reaction by adding 10µM OAA to each well simultaneously. Again, we 
recorded TNB absorbance at 412nm at 10 second intervals for a total of 80 seconds. The 
endogenous enzyme activity was subtracted from the total CS activity following the OAA 
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addition, giving us the net CS activity. Each condition was tested in triplicate for n=4 in 
Group 2 and n=3 in Group 3. 
 We found that at 12 months of age, the rate of conversion of DTNB to TNB by CS in 
fast-twitch muscle did not differ between WT and VCPR155H/+ (Figure 3.11, C). However, at 
14 months, the temporal development of TNB was slower in fast-twitch muscle from 
VCPR155H/+ mice (Figure 3.11, D). We then calculated the enzyme activity, in µmoles/ml/min, 
and compared the averages of each condition for the two age groups using a two-tailed 
independent t-test. The results are represented in Figure 3.11, E.  
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Figure 3.11 Mitochondrial respiratory complex enzyme activity in fast-twitch muscle from 
age-matched WT and VCPR155H/+ mice. EDL lysates were assayed for citrate synthase (CS) 
activity to compare aerobic capacity of fast-twitch muscles from age-matched WT and 
VCPR155H/+. Baseline CS activity was assayed in order to measure and eliminate endogenous 
thiol and deacetylase activity from the assay (A and B).  Following the addition of the 
substrate 10mM oxaloacetate solution, the absorbance at 412nm was read by a plate 
reader every 10 seconds for 80 seconds and the baseline CS activity was subtracted from 
the total CS activity in order to calculate the net CS activity (C and D). At 14 months (Group 
3), the CS activity (as measured in µmole/min/ml) was found to be lower in VCPR155H/+ EDL, 
suggesting decreased mitochondrial function at 14 months in VCPR155H/+ fast muscle when 
compared with WT control (E). This difference was not found to be statistically significant 
(n=4 in Group 2, n=3 in Group 3). Asterisk indicates p<0.05. 
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 CS activity, at 14 months of age, was significantly lower in VCPR155H/+ fast-twitch 
muscle when compared with WT (p=0.0418). This may indicate the presence of a defect in 
the oxidative pathways of fast-twitch skeletal muscle of VCPR155H/+ mice, which presents at 
the previously outlined ‘critical’ age of 14 months. It is worth noting that, while the p-value 
given by the student’s t-test is valid, this result cannot be overstated due to the small 
sample size. 
 To verify that the difference in CS enzyme activity was not due to lower 
mitochondrial content in VCPR155H/+ fast-twitch fibres, we quantified the expression of the 
outer mitochondrial membrane translocase TOMM20 using Western blotting and the 
Odyssey Infrared Imaging system (Licor) (Figure 3.12). There were no significant differences 
in TOMM20 expression between WT and VCPR155H/+ in either Group 2 or Group 3, 
confirming that the mitochondrial content was the same in these tissues (Figure 3.12).  
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Figure 3.12 No significant difference in mitochondrial protein expression in fast-twitch 
muscle (EDL) between WT and VCPR155H/+ in Groups 2 and 3. Lysates of EDL from Groups 2 
(A) and 3 (C) were analysed by Western blotting to determine total mitochondrial content 
using an antibody against the outer mitochondrial membrane translocase TOMM20. No 
significant differences in TOMM20 expression were observed between WT and VCPR155H/+ 
fast muscle samples from any of the three groups. Samples were run in biological triplicate.  
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3.3 Discussion 
 The predominant pathophysiological symptom of IBMPFD is late-onset progressive 
muscle weakness and degeneration. In order to investigate whether VCP mutation affects 
skeletal muscle in a fibre-specific manner, we subjected fast- and slow-twitch muscle fibre 
bundles to a fatigue protocol, and assessed any changes in specific force production and 
fatigue tolerance (Figure 3.1 and 3.3, A-E).  
 At 5.5 – 6.5 months of age (Group 1), there was no apparent difference between 
VCPR155H/+ mutant and wild type mice with regard to the actual specific force produced by 
fast-twitch fibres when the values are normalised to P0. However, as the mice approach one 
year of age, the normalised specific force produced by VCPR155H/+ mutant fast-twitch fibres 
decreases significantly from contraction 40 onwards, and the post-FP recovery time is 
significantly longer than in the wild type. Interestingly, this decline becomes more 
pronounced at 14 months (Group 3; Figure 3.3, C and D), suggesting that fast-twitch fibres 
from VCPR155H/+ mice are significantly more susceptible to fatigue-related force decline than 
wild type age-matched control fibres. An important point to note is that in Group 3, 75% of 
all VCPR155H/+ fast-twitch muscle fibre bundles tested did not recover to ≥90% P0. This was 
the parameter used to distinguish between decreases in force production due to VCPR155H/+ 
mutation and fibres that were dying during the fatigue protocol. This high proportion of 
‘non-recovered’ fibres suggests that this is the critical age at which the functional 
biomechanical effects of VCPR155H/+ mutation on fast-twitch muscle are most severe.  
 In contrast to the apparent functional consequences of VCPR155H/+ expression on 
normalised specific force production by fast-twitch fibres, there appeared to be minimal 
effects of VCPR155H/+ mutation on slow-twitch fibre fatigue characteristics. Fatigue in this 
case is defined as any reversible decrease in peak force resulting from the repeated tetanic 
stimulation of muscle. When normalised to P0, a decrease in normalised force production 
and fatigue tolerance in VCPR155H/+ mutant slow fibres can be seen from 13.2 – 14.8 months 
of age (Group 3) onwards, however this was not found to be significant when the VCPR155H/+ 
mutant and wild type results were compared using an ANOVA (p = 0.199; Figure 3.4, C).   
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 As previously outlined, the soleus muscle contains primarily oxidative muscle fibres. 
This fibre type expresses the MHC type I and IIA isoforms, utilizes the oxidative 
phosphorylation pathway as its main energy source and is rich in mitochondria in order to 
facilitate this. The MHC isoform expressed in a muscle fibre correlates directly with the 
speed at which the muscle contracts, as the ATP hydrolysis rate determines the speed of 
cross-bridge cycling and therefore sarcomere-shortening (Floeter et al., 2010). Fatigue 
resistance is a characteristic which results from the oxidative respiration used by slow 
fibres; therefore sustained submaximal contractions under aerobic conditions represent a 
key biomechanical function of this fibre type. In contrast, type II or fast-twitch fibres contain 
glycolytic enzymes which produce the majority of ATP used for muscle contraction; 
however, the reliance on glycogen stores, which become depleted following repetitive 
muscle stimulation, means that these fibres are susceptible to fatigue at varying levels, 
depending on MHC isoform expression. Type IIA fibres are the most fatigue resistant fast 
fibres, type IIB are the least resistant to fatigue and type IIX are classified as intermediate.  
 Our results led us to examine the fibre-type composition of the fast-twitch muscles 
from age-matched WT and VCPR155H/+ mice. Firstly, all fibres in EDL were found to be fast-
twitch when MHC-F and MHC-S antibodies were used on sequential cryosections (Figure 
S.5, supplementary data). To further investigate the composition of the muscle, we used 
antibodies raised against the fast-glycolytic fibre subtype MHC-IIB and cytochrome c 
oxidase subunit IV (COX-IV), the terminal complex of the electron transfer chain in 
mitochondria. Fibres which immunostained positively with the MHC-IIB antibody were 
classified as fast-glycolytic (FG), the fibres which stained with the COX-IV antibody and 
therefore displayed high mitochondrial content were classified as fast-oxidative (FO) and 
finally fibres in which faint COX-IV staining was observed along with MHC-IIB 
immunoreactivity were considered intermediate or fast-oxidative-glycolytic (FOG).  
 The three fibre types were counted and the ratio in which they were found in EDL 
from age-matched WT and VCPR155H/+ was determined and compared. This allowed us to 
determine any differences in the MHC isoform expression and therefore the metabolic 
profiles of VCPR155H/+ fast-twitch muscles, which might explain the fatigue intolerance. 
Previous studies have reported a marked variation in muscle fibre size in quadriceps (mixed 
MHC isoform expression) from patients expressing VCP mutations (Watts et al., 2007), with 
atrophy reported in type I fibres in several cases (Stojkovic et al., 2009). It was therefore 
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important for us to investigate whether our VCPR155H/+ knock-in mouse model exhibited 
similarities with regard to fibre size distribution and relative fibre type ratio in EDL.  
 No significant differences between fibre type ratio and EDL composition were 
revealed following visual scoring and analysis of cryosections from 12 and 14 month old WT 
and VCPR155H/+ mouse hind limbs (Figures 3.8 and 3.9). The fibre type ratios in EDL from 
both WT and VCPR155H/+ mice at 12 months were comparable to those in previous studies 
(Augusto et al., 2004). At 14 months, the ratio of fast oxidative fibres (type IIA) increases in 
both WT and VCPR155H/+ EDL. This trend is surprising, as the fatigue tolerance of fast-twitch 
fibre bundles at this age was significantly lower in VCPR155H/+ mice. A fast-to-slow fibre type 
shift is associated with aging (Nilwik et al., 2013), however two months would not be a long 
enough time period for this shift to occur. At 27 months, fast-twitch fibre bundles from 
VCPR155H/+ mice performed as well as WT age-matched controls in muscle biomechanics 
experiments (Figure 3.3, E). Mizushima and colleagues (2004) reported a starvation-
induced increase in autophagosome formation in EDL, but not in soleus, therefore fast-
twitch fibres may be more susceptible to the effects of a dysfunctional autophagic pathway 
than slow-twitch (Mizushima et al., 2004). As Ju and colleagues (2009) observed, mutations 
in VCP lead to the build-up of immature autophagosomes (Ju et al., 2009), therefore if 
autophagy is activated more readily in fast-twitch fibres, autophagic dysfunction may affect 
fast-twitch fibres to a greater degree than slow. To that end, EDL in very aged animals (27 
months) may have undergone a glycolytic-to-oxidative fibre type transition, as a result of 
both the aging process and a decrease in type II fibres. Analysis of EDL fibre type 
composition in very aged animals may provide insight into this hypothesis. Another 
possible explanation for the absence of muscle dysfunction in very aged mice may be that 
the myopathic phenotype resulted in the early death of those animals in which it was 
expressed, and therefore the animals that survived to 27 months may not have been as 
severely affected by this phenotype. Indeed, negative selection of the myopathic 
phenotype may have enabled some animals to survive until 27 months. 
 When fibre size distribution was compared statistically using a Mann-Whitney test, 
we found that the areas of both fast-glycolytic (MHC-IIB-positive) and fast-oxidative (COX-
IV-positive) fibres were larger in EDL from 12 month old VCPR155H/+ mice when compared 
with WT controls. At 14 months, the areas of VCPR155H/+ fast-glycolytic and intermediate 
fibres was significantly larger than in WT EDL. Under normal conditions, increased muscle 
fibre size is accompanied by an increase in muscle strength (Frontera et al., 1988). Piccirrilo 
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and colleagues (2012) demonstrated that tibialis anterior muscles which had been 
electroporated with plasmid encoding a dominant negative ATPase-deficient VCP mutant, 
VCPK524A, were significantly larger than those treated with WT-VCP (Piccirillo et al., 2012). 
However, in contrast to our work, the study did not find any significant differences in size 
between fibres electroporated with the IBMPFD mutant VCP-R155H plasmid and those 
treated with WT-VCP. The apparent hypertrophy of certain fibre types in our studies does 
not seem to accompany an increase in functional strength, as whole muscle studies of EDL 
reveal that even at 15 months of age, force production by whole EDL muscles from WT and 
VCPR155H/+ mice did not differ in terms of specific force (manuscript, in progress). 
 The discovery that fast-twitch muscles isolated from aged VCPR155H/+ mice fatigued 
to a greater degree than WT controls prompted us to investigate potential mechanisms by 
which the reduced fatigue resistance may be occurring. Baker et al. (2010) outlined the 
interactions between the three energy-providing metabolic systems in skeletal muscle 
during exercise. The energy provided by phosphocreatine (PCr) conversion spikes very early 
during a 100sec long bout of exercise (at around 5secs) and is seen to decrease sharply 
thereafter. ATP generated via glycolytic respiration peaks at around 40 seconds into the 
exercise, after which it gradually drops. However, ATP turnover from mitochondrial 
respiration only begins to peak after approximately 100 secs of exercise (Figure 3.13). 
Therefore, it would be reasonable to suggest that the fatigue-induced decrease in force we 
discovered in aged VCPR155H/+ mice may result in part from compromised ability of the 
mitochondrial network to generate ATP optimally during exercise. 
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Figure 3.13 Interaction of energy systems and differences in ATP turnover rate during 
short-term exercise to fatigue in skeletal muscle. During the transition from rest to 
activity, immediate ATP regeneration is facilitated by the dephosphorylation of 
phosphocreatine by creatine kinase to produce ADP and Pi (red line). Longer term 
contractile activity is supported by ATP generation via oxidative phosphorylation in 
mitochondria; a process which is more effective in slow-twitch muscles due to the higher 
mitochondrial content (blue line). Intermediate energy requirements are met via glycolysis 
(green line) (Adapted from Baker, 2010 (review)).  
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 In order to investigate this theory, we assayed mitochondrial enzyme activity in 
fast-twitch muscles isolated from age-matched group 2 and 3 mice, specifically that of 
citrate synthase. CS is described as the pace-making enzyme for the TCA cycle, in which it 
catalyses the condensation reaction between acetyl coenzyme A (acetyl CoA) and 
oxaloacetic acid (OAA) to form citric acid. Maximal CS activity is routinely used as a marker 
of aerobic capacity and mitochondrial density in skeletal muscle (Stump et al., 2003, Delp et 
al., 1996).  
 Interestingly, we found lower overall CS activity in fast-twitch muscles (EDL) from 
VCPR155H/+ mice aged 14 months (Group 3). This is the age at which isolated VCPR155H/+ 
mutant fast-twitch fibre bundles not only fatigue to a greater extent than their WT control 
counterparts, but also take significantly longer to recover isometric force to ≥90% P0 post-
FP.  
 From these data, we propose that there is a defect in maintaining mitochondrial 
network integrity in VCPR155H/+ mutant mice, which manifests pathologically in muscle at 14 
months. It has been shown that VCP is involved in shuttling oxidatively-damaged 
mitochondrial proteins to the proteasome, so it would be reasonable to suggest that the 
decreased function of the mitochondrial network (as evidenced by fatigue intolerance and 
diminished TCA cycle function), is due to the accumulation of damage over time. Indeed, 
the effects of VCP mutation on the removal of damaged mitochondrial proteins are not 
lethal, as the mice survive to well beyond 2 years. However, failure to adequately maintain 
mitochondrial quality control mechanisms, via the removal and degradation of these 
damaged proteins, would be detrimental to the network integrity and thus the ability of 
the muscle fibres to resist fatigue through longer-term ATP generation. To that end, 
researchers have recently discovered altered mitochondrial dynamics and bioenergetics in 
primary fibroblasts isolated from patients harbouring the VCP-R155H mutation (Nalbandian 
et al., 2015). Using Seahorse XF-24 flux analysis (which measures the oxygen consumption 
and glycolysis rates in cells in vitro), it was revealed that in VCP-R155H fibroblasts, ATP 
content and spare respiratory capacity (a measure of the extra ATP that can be produced 
by oxidative phosphorylation under stressful conditions) was decreased, and increased 
proton leak (suggestive of a decrease in mitochondrial membrane integrity) and 
extracellular acidification rate (ECAR; indicative of levels of glycolysis) were increased. 
These results provide a possible explanation for the fatigue intolerance observed in 
VCPR155H/+ fast-twitch skeletal muscle our experiments. Again, it is important to note that 
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the muscle mechanics data obtained from the very aged mice do not support this theory. 
Therefore further investigations into the mechanism by which these mice either evade age-
dependent muscle dysfunction or regain fast-twitch muscle functional capacity later in life 
are warranted. 
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Chapter 4: Effect of VCP mutant 
expression on mitochondrial 
dynamics in vitro 
 
4.1 Introduction 
 In text books, mitochondria are generally depicted as solitary organelles, but now 
they are understood to be continually involved in fission and fusion events with one 
another, leading to a dynamic interconnected filamentous network. The energy status and 
metabolic demands of the cell initiate and dictate these changing network configurations. 
While the principle function of mitochondria is to maintain cellular homeostasis, their 
dysfunction can prove lethal to the cell, specifically via the generation of reactive oxygen 
species (ROS), which damage DNA and stimulate apoptosis (Campello et al., 2014). 
Mitochondrial quality control involves the removal of damaged mitochondria from the 
network in order to maintain functional integrity. The selective autophagic degradation of 
whole mitochondria, termed mitophagy, occurs when the organelle becomes irreparably 
damaged (Figure 1.5). In order to segregate the single dysfunctional mitochondrion from 
the network, a highly-regulated protein degradation cascade occurs (Tastuda et al., 2008; 
Chan, 2012 (review)).  It is becoming evident that the degradation of these proteins and 
thus the molecular control of mitochondrial dynamics is governed by a ubiquitin-protein 
degradation pathway (Tanaka et al., 2010, Kim et al., 2013, Ashrafi et al., 2013).  
 Both the inner and outer mitochondrial membranes must be divided sequentially, 
to prevent the matrix contents from leaking into the cytosol. Outer mitochondrial fusion 
proteins, such as Mfn1 and 2, are degraded by the ubiquitin-proteasome system (UPS) 
(Tanaka et al., 2010). Such proteins become ubiquitinated by the E3 ubiquitin ligase Parkin, 
thus targeting them for degradation. Under homeostatic conditions, Parkin is diffusely 
localised in the cytosol. Loss of mitochondrial membrane potential acts as a signal to Parkin 
to translocate to the mitochondrial network and facilitate the removal of dysfunctional 
proteins via ubiquitination. Studies have demonstrated that the expression of mutated VCP 
prevents the proteasomal degradation of ubiquitinated Mfn1 and 2 (Kim et al., 2013, 
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Tanaka et al., 2010). The role of VCP in Parkin-dependent mitophagy is depicted in Figure 
1.5.  
There are two indications that mitochondria may have a role in the pathology seen in 
IBMPFD:  
1. Swollen mitochondria have been observed in skeletal muscle of IBMPFD disease 
model animals by Badadani and colleagues (Badadani et al., 2010) 
2. The age-dependent fatigue intolerance of fast-twitch skeletal muscle fibre bundles 
we observed in VCPR155H/+ mice.  
This prompted us to examine the effects of mutated VCP expression on two inexorably 
linked characteristics of mitochondria – morphology and function.  
 
 
 Initially, to investigate the possible effects of overexpressing the IBMPFD-
associated VCP mutant, VCP-R155H, on mitochondrial morphology, we transiently over-
expressed EGFP-tagged plasmids encoding both wild type and the clinically relevant R155H-
mutated VCP in MEF cells. Mitochondria were stained using MitoTracker CMXRos - a red 
cell-permeant mitochondrion-selective dye which diffuses passively across the plasma 
membrane and accumulates in active mitochondria but not inactive/defective 
mitochondria. The cells were incubated in 300nM MitoTracker CMXRos dye in complete 
DMEM and once the mitochondria were labelled (following an incubation time of 25 
minutes); the cells were fixed with 4% PFA to enable further processing and visualisation.  
 In a complementary approach (and to overcome the limitations of transient 
transfections) we also isolated and cultured primary skin-derived fibroblasts from our 
VCPR155H/+ knock-in mice to investigate the effects of endogenous expression of the 
IBMPFD-associated VCP mutation R155H on mitochondrial dynamics under both steady 
state and oxidative stress conditions, induced by the addition of carbonyl cyanide m-
chlorophenylhydrazone (CCCP), a reversible mitochondrial uncoupling agent. Experiments 
were completed in biological triplicate for each condition. 
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4.2 Results 
 
4.2.1.1 Transfected EGFP-tagged VCP variants are diffusely 
distributed in the cytosol in MEFs under control conditions  
The pathologic R155H mutation did not affect the diffuse cytoplasmic localisation of VCP 
under control conditions. MitoTracker CMXRos was used to stain mitochondria with intact 
membrane potential and the filamentous networks could be clearly seen in non-
transfected cells, and EGFP-tagged WT- and R155H-VCP transfected cells (Figure 4.1).  
 
 
4.2.1.2 Dissipation of the mitochondrial membrane potential does 
not affect the cellular localisation of VCP in transfected MEF cells  
Transfected MEF cells were treated for 3 hours with 50uM CCCP 24hrs post-transfection. 
Live mitochondria were stained using MitoTracker CMXRos. Diffuse VCP staining was 
observed both in cells transfected with plasmids encoding EGFP-tagged WT-VCP and VCP-
R155H. No translocation of VCP to the mitochondrial network upon membrane 
depolarisation by CCCP was observed (Figure 4.1). Overexpression of EGFP-VCP-R155H did 
not affect the ability of the mitochondrial network to fragment upon CCCP treatment, as 
rounded MitoTracker CMXRos-positive organelles could be seen clearly in both these cells 
and those transfected with EGFP-tagged WT-VCP. Tanaka and colleagues (2010) reported 
on the CCCP-induced accumulation of endogenous wild type VCP on mitochondria in HeLa 
cells transiently expressing YFP-Parkin. Therefore, the failure of EGFP-tagged VCP variants 
to localise with uncoupled mitochondria in MEF cells in our experiments was to be 
expected, as MEF cells lack Parkin expression (Matsuda et al., 2010, Tanaka et al., 2010). 
These preliminary experiments confirmed the findings of previous publications (Tanaka et 
al., 2010). Next, we chose to further examine in detail the effects of endogenous levels of 
VCP-R155H on mitochondrial dynamics under homeostatic conditions and in response to 
oxidative stress.  
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Figure 4.1 Transfected EGFP-tagged VCP variants do not colocalise with mitochondria in 
MEF cells under control conditions (A) nor when exposed to oxidative stress (B). (A) The 
pathogenic R155H mutation did not affect the diffuse cytoplasmic localisation of VCP under 
control conditions. MitoTracker CMXRos was used to stain mitochondria with intact 
membrane potential and the filamentous networks can be clearly seen in both WT and 
R155H-VCP transfected cells. (B) CCCP treatment did not affect the cellular localisation of 
VCP in MEF cells. Transfected MEF cells were treated for 3 hours with 50µM CCCP 24hrs 
post-transfection. Live mitochondria were stained using MitoTracker CMXRos. Diffuse VCP 
staining is observed both in cells transfected with EGFP-tagged WT-VCP and R155H-VCP. No 
translocation of VCP to the mitochondrial network upon membrane depolarisation by CCCP 
is seen (Scale bar = 20µm). 
 
88 
 
4.2.2.1. Similar cytosolic distribution of endogenous WT- and 
R155H-mutant VCP in primary skin-derived fibroblasts under 
steady state conditions 
We next sought to investigate whether the expression of physiological levels of VCPR155H 
had any effect on:  
(i) The morphology of the mitochondrial network under control conditions. 
(ii) The ability of the mitochondrial network to fragment under conditions of 
oxidative stress.  
Our knock-in animal model of IBMPFD was integral to this work – we isolated and cultured 
primary fibroblasts from skin biopsies of young (<3 months of age) WT and VCPR155H/+ mice 
and performed immunofluorescence microscopy on the cells by immunostaining 
endogenous VCP with rabbit monoclonal anti-VCP antibody. As with the MEF cell 
transfections, MitoTracker CMXRos was used to stain mitochondria. As shown in Figure 4.2, 
diffuse staining of VCP was seen in the cytosol, with nuclear staining also observed in 
fibroblasts derived from both WT-VCP and VCPR155H/+ mutant mice. VCP is known to play a 
role in piecemeal microautophagic degradation of the nucleus in yeast; therefore this 
localisation was not considered unusual (Krick et al., 2010). 
 
Initially, we visually scored the fibroblast cell images and classified the VCP distribution 
patterns in three categories – (i) diffuse, (ii) diffuse with some puncta and (iii) punctate. We 
also scored the mitochondrial morphology in cells as (i) tubular, (ii) fragmented (small 
rounded mitochondria seen) or (iii) intermediate (swollen sections within tubular 
mitochondria). Images were numbered randomly by a colleague and scored blindly to avoid 
bias.  We found that both wild type VCP and VCPR155H/+ remained diffusely distributed in the 
cytosol and no colocalisation of VCP with mitochondria was observed under control 
conditions (Figure 4.2 (A)).  
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Figure 4.2 Cytoplasmic distribution of endogenous VCP in primary fibroblasts isolated 
from WT and VCPR155H/+ mice under (A) control and (B) oxidative stress conditions. 
Endogenous VCP in primary murine fibroblasts was stained using a rabbit monoclonal anti-
VCP antibody. Mitochondria were stained with MitoTracker CMXRos and nuclei stained 
with DAPI. (A) Note the filamentous mitochondrial network and diffuse cellular VCP 
staining under control conditions. (B) Following CCCP treatment, punctate VCP aggregates 
were observed throughout the cytoplasm, while the fragmented mitochondria clustered in 
the perinuclear region. VCP does not appear to colocalise with mitochondria under control 
nor stress conditions (insets) (Scale bar = 20µm). 
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4.2.2.2. Endogenous expression of pathogenic VCPR155H does not 
affect mitochondrial fragmentation upon CCCP treatment on visual 
scoring 
 Following CCCP treatment, the mitochondrial network fragmented in both WT-VCP 
and VCPR155H/+ expressing cells (Figure 4.2(B)). Interestingly, both WT- and R155H-mutant 
VCP formed punctate aggregates when exposed to oxidative stress; however these puncta 
did not colocalise with the fragmented mitochondria (Figure 4.2 (B) insets).  
 Western blotting using lysates of these cells revealed low yet comparable 
expression of endogenous Parkin in both WT and VCPR155H/+ primary fibroblasts (when 
compared with a lysate of brain from a WT mouse), again emphasising the necessity of 
Parkin in the translocation of VCP to mitochondria under conditions of oxidative stress 
(Figure 4.3). In summary, the presence of the R155H mutation in VCP neither impeded nor 
enhanced its colocalisation with the mitochondrial network, and the dissipation of the 
mitochondrial membrane potential and fragmentation of the network by CCCP treatment 
did not induce the translocation of VCP to mitochondria in cells with low Parkin expression 
(Matsuda et al., 2010). Under control conditions, VCP was mainly diffusely distributed 
throughout the cytoplasm in both WT and VCPR155H/+ fibroblasts (average scoring of 75% of 
WT cells and 68% VCPR155H/+ cells displayed diffuse VCP staining). Following a 3 hour 
incubation with 50µM CCCP to induce mitochondrial uncoupling, VCP puncta were 
observed in both WT and VCPR155H/+ cells (Figure 4.4). Figure 4.5 represents visual scoring of 
mitochondrial morphology in primary WT and VCPR155H/+ fibroblasts under control 
conditions and under conditions of oxidative stress. 
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Figure 4.3 Expression of endogenous Parkin in primary WT and VCPR155H/+ fibroblasts. 
Lysates of cultured primary fibroblasts from WT and VCPR155H/+ mice were run on a 4-12% 
Bis-Tris precast gel (Novex) for 1hour at 120V. MagicMark XP ladder was used to determine 
band size. Mouse anti-actin and rabbit anti-Parkin were used to immunolabel the blot. 
Signal intensity was measured using LiCor Odyssey analysis software and graphed. Parkin 
expression was found to be lower in both WT and VCPR155H/+ fibroblasts than in brain lysate 
from WT mouse (B; approximately 8-fold difference in endogenous Parkin expression) with 
comparable expression observed between WT and VCPR155H/+ fibroblasts. 
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Figure 4.4 Visual scoring of endogenous cytoplasmic VCP distribution in primary (A) WT 
and (B) VCPR155H/+ fibroblasts under control conditions and following exposure to 
oxidative stress. Under control conditions, VCP was mainly diffusely distributed throughout 
the cytoplasm in both WT and VCPR155H/+ cells (average scoring of 75% of WT cells and 68% 
VCPR155H/+ cells displayed diffuse VCP staining). Following 3 hour incubation with 50µM 
CCCP to induce mitochondrial uncoupling, VCP puncta were observed in both WT and 
VCPR155H/+ cells (average number of cells scored per condition = 23). 
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Figure 4.5 Expression of VCPR155H does not hinder the ability of the mitochondrial network 
to fragment following uncoupling. Graphic representation of mitochondrial morphological 
conformation under control conditions and when exposed to oxidative stress. Morphology 
was scored visually in each cell and classified as tubular, fragmented (small rounded 
mitochondria) or intermediate (swollen parts within tubular mitochondria). Interestingly, 
while 71% of WT fibroblasts displayed a tubular network of mitochondria, the mitochondria 
in VCPR155H/+ fibroblasts were classified as mainly intermediate (75% of cells scored showed 
intermediate mitochondrial morphology). Scoring was performed blind. (Average number 
of cells scored per condition = 23). 
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 These results are in line with the observations of Tanaka and colleagues (2010), 
showing that in HeLa cells lacking Parkin, VCP failed to translocate to depolarised 
mitochondria. Interestingly, both WT-VCP and a catalytically dead VCP mutant, 
VCPE305Q/E578Q, colocalised with mitochondria following CCCP treatment, indicating that 
ATPase activity is not required for this colocalisation. It has been demonstrated that the 
R155H mutant has normal ATPase activity (Weihl et al., 2006), therefore we wanted to 
investigate, in a more quantitative way, how the expression of the R155H mutant might 
affect mitochondrial dynamics. We decided that spatial three-dimensional analysis of the 
mitochondrial networks, under both homeostatic and oxidatively stressful conditions, 
would be a good method of revealing any such effects. 
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4.2.3.1 Three dimensional analysis of mitochondrial dynamics in 
primary fibroblasts 
 In order to examine mitochondrial dynamics in the context of mutant VCP 
expression in the native cellular environment, we successfully isolated primary skin-derived 
fibroblasts from WT and VCPR155H/+ mice.  Analysis of mitochondrial morphology in a three 
dimensional way involved acquiring high resolution z-stacked microscope images across the 
depth of fixed fibroblasts in which the mitochondria were again labelled using MitoTracker 
CMXRos.  
 These images were then processed using Imaris analysis software (Bitplane), which 
delivers a numerical summary describing several mitochondrial characteristics of a given 
cell – surface area (in µm2), volume (in µm3) and sphericity (value between 0.0001 and 1, 
with the sphericity of a perfect sphere being equal to 1). A single cell was demarcated using 
the Region of Interest function. Intensity thresholding was used in order to accurately 
differentiate between true mitochondria pixels and background fluorescence (Westrate et 
al., 2014).  The thresholding of each image ensured that each image was analysed in a 
consistent way – enabling the standardised selection of mitochondrial objects in the cells. 
The software then generated a 3D rendering, or ‘isosurface’, of the networks, and from this 
rendering the characteristics of the mitochondria were deduced and exported into an Excel 
spreadsheet for analysis. The mitochondria were categorised into bins based on their 
volumes, (1-10µm3, 11-100µm3 and 101-1000µm3; with mitochondrial objects smaller than 
1µm3 not considered to be true mitochondria and excluded from the analysis) and the 
volumes of the mitochondrial objects of 5 cells from three WT and three VCPR155H/+ animals 
were compared using an ANOVA on ranks with Tukey post-hoc analysis (Figure 4.6). The 
analysis was blinded by denoting each cell with the identification number of the mouse 
from which it was derived, while the genotyping of these animals was carried out 
separately by another member of the lab. 
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Figure 4.6 Quantitative analysis of mitochondrial volumes in primary WT and VCPR155H/+ 
fibroblasts under control conditions and following 3 hour 50µM CCCP treatment. Under 
control conditions, the mitochondrial volumes in both WT and VCPR155H/+ cells span a range 
from 1-184.4µm3 in WT and 1-234.05µm3 in VCPR155H/+ cells, indicative of the continuous 
fission and fusion events occurring to maintain mitochondrial network quality control 
under steady state conditions. These volumes were found to be significantly different, even 
under control conditions (p=0.125; WT median volume = 1.092; VCP VCPR155H/+ median 
volume = 0.9321). As expected, in WT cells a significant decrease of the mitochondrial 
volume range is observed following CCCP treatment (median WT control volume = 
1.092µm3 compared with 0.6434µm3 following CCCP incubation; p<0.0001). While in 
VCPR155H/+ cells, the mitochondrial network did fragment significantly following CCCP 
incubation (median VCPR155H/+ control volume = 0.9321µm3 decreased to 0.5125µm3 after 
CCCP treatment; p<0.0001), several large components of the network remained, with the 
largest of these measuring 134.73µm3. The significant difference in mitochondrial 
fragmentation is seen when comparing CCCP-treated WT and VCP fibroblasts (p<0.0001). 
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4.2.3.2 Comparison of mitochondrial volumes in WT and VCPR155H+ 
fibroblasts under control conditions 
 A two-way ANOVA comparing mitochondrial volumes across the four conditions 
(WT, VCPR155H/+, control and CCCP-treated) showed significant differences between 
genotypes and treatments. Tukey post-hoc analysis revealed significant differences in 
mitochondrial volumes between primary WT and VCPR155H/+ fibroblasts under control 
conditions (p = 0.00125). Under control conditions, the mitochondrial volumes in WT and 
VCPR155H/+ cells span a range from 1-184.4µm3 and 1-234.05µm3  respectively, indicative of 
the continuous fission and fusion events occurring to maintain mitochondrial network 
quality control under steady state conditions. Interestingly, statistical analysis showed 
these volume ranges to be significantly different (p=0.00125), with the median volume in 
WT fibroblasts measuring 1.092µm3 (n = 3725) and 0.9321 µm3 in VCPR155H/+ fibroblasts (n = 
4011).  
 
 
4.2.3.3 CCCP treatment induced fragmentation of the mitochondrial 
networks to a greater extent in primary WT fibroblasts when 
compared with VCPR155H/+ cells  
 As expected, in WT-VCP expressing fibroblasts, the mitochondrial network 
fragmented following dissipation of the membrane potential by CCCP incubation, as 
indicated by the significant decrease of the mitochondrial volume range (median WT 
control volume = 1.092µm3 compared with 0.6434µm3 following CCCP incubation; 
p<0.0001). While the mitochondrial network did fragment significantly in VCPR155H/+ cells 
following CCCP incubation (median VCPR155H/+ control volume of 0.9321µm3 decreased to 
0.5125µm3 after CCCP treatment; p=0.0118); several large components of the 
mitochondrial network remained, with the largest of these measuring 134.73µm3. This may 
suggest that VCP-R155H mutation hinders the ability of the mitochondrial network to 
fragment completely following exposure to conditions of oxidative stress (Figure 4.6). 
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4.2.4 Comparison of total mitochondrial content in primary WT and 
VCPR155H/+ fibroblasts 
 In order to investigate whether the differences in mitochondrial volumes were due 
to either inefficient degradation of the mitochondrial fusion proteins resulting from the 
expression of the IBMPFD mutant VCPR155H or possible differences in the total 
mitochondrial content, we utilised a Western blot in which mitochondrial content was 
measured by probing for TOMM20, an outer mitochondrial membrane translocase protein 
of 16kDa. We found that TOMM20 expression levels were similar in WT and VCPR155H/+ cells 
(Figure 4.7). This provides evidence that the differences observed in CCCP-induced 
mitochondrial fragmentation may be due to the expression of the VCP mutation in these 
cells. Cells with continuously high metabolic demands, such as those found in brain, would 
be expected to have high capacity for oxidative phosphorylation for energy production and 
therefore high mitochondrial content. This can be seen in the TOMM20 band of brain 
lysate from WT mouse, where normalised TOMM20 expression is increased 5-fold in 
comparison with TOMM20 expression in primary fibroblasts (Figure 4.7).  
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Figure 4.7 No significant differences in total mitochondrial content between primary WT 
and VCPR155H/+ fibroblasts. TOMM20 is routinely used as a marker for total mitochondrial 
content. Western blotting of WT and VCPR155H/+ fibroblast lysates showed low yet 
comparable expression of TOMM20, indicating similar mitochondrial content. WT brain 
lysate is used as a control of tissue with high metabolic demand therefore high 
mitochondrial content. (n=3 biological replicates for WT and VCPR155H/+). 
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4.3. Discussion 
 Mitochondria are dynamic structures possessing great plasticity with regard to 
morphological remodelling. Various stimuli can induce drastic structural transformation of 
the mitochondrial network which can in turn impact upon the activity of mitochondrial 
enzyme complexes and thus on overall bioenergetic capacity (Brustovetsky et al., 2009). 
Numerous studies have provided evidence of the tightly regulated relationship between 
mitochondrial network conformation and ATP generation (Benard et al., 2006). 
Considerable structural remodelling of the networks was observed in HeLa cells cultured in 
a glucose-free, galactose- and glutamine-rich medium when compared with those growing 
in glucose-rich growth conditions, indicative of a profound morphological effect of 
switching from glycolysis to oxidative phosphorylation for ATP generation (Rossignol et al., 
2004). Under conditions in which glucose was freely available, the mitochondrial network 
was shown to cluster in the perinuclear region. However, when oxidative phosphorylation 
was stimulated, the network adopted a more reticular conformation, with the looped 
structures extending into the cytoplasm, possibly to facilitate provision of ATP to all parts 
of the cell (Rossignol et al., 2004).   
 It follows from this that under- or overexpression of mitochondrial fusion and 
fission proteins would affect network conformation and subsequent bioenergetics. Indeed, 
antisense adenoviral-mediated Mfn2 knock-down in muscle cells resulted in decreased 
substrate oxidation, decreased mitochondrial membrane potential and down-regulation of 
subunits of oxidative phosphorylation complexes I, II, III and IV (Pich et al., 2005). The 
opposite pattern was observed in Mfn2-overexpressing cells, with increased OXPHOS 
subunit expression reported (Pich et al., 2005). Moreover, siRNA targeting of the 
mitochondrial fission protein Drp1 in HeLa cells resulted in abnormal branching and 
budding of the network concurrent with a reduction in mitochondrial ATP synthesis rate 
(Benard et al., 2006). These studies underscore the importance of the morphological 
plasticity of the mitochondrial network in the context of fulfilling the fluctuating metabolic 
demands of the cell.  
 Therefore, it was important to investigate the possible impact of VCP mutation on 
the remodelling potential of mitochondrial networks, particularly in light of our discovery 
of fast-twitch muscle fibre-specific fatigue intolerance. Initial examination of fluorescently 
tagged EGFP-VCP transfected MEF cells revealed similar diffuse cytoplasmic distribution of 
both WT-VCP and VCP-R155H. Mitochondrial network structure did not seem to differ in 
MEF cells overexpressing WT and the R155H mutant VCP, with tubular mitochondrial 
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conformation observed in both under control growth conditions. In order to induce 
OXPHOS uncoupling and fragmentation of the mitochondrial network, we used the 
reversible protonophore CCCP, which causes proton leak from mitochondria, resulting in 
the dissipation of the mitochondrial membrane potential. We found that EGFP-tagged WT 
and VCPR155H remained diffusely located throughout the cytoplasm of CCCP-treated cells. 
The mitochondrial network fragmented following 3 hours of CCCP incubation, and neither 
WT-VCP nor VCPR155H colocalised with the fragmented mitochondria (Figure 4.1). 
Interestingly, CCCP incubation appeared to induce nuclear localisation of transfected EGFP-
VCP-WT in some cells (Figure 4.1). This effect was also occasionally observed in primary 
fibroblasts from both WT and VCPR155H mutant mice, but was not consistent for any one 
condition, therefore cannot be considered an effect of oxidative stress on the localisation 
of VCP. However, CDC48 in yeast and VCP in humans have both been shown to relocalise 
throughout the course of the cell cycle, with VCP accumulating at the centrosomes during 
mitosis (Madeo et al., 1998), therefore it may indicate the stage of the cell cycle the 
particular cell is in. In addition, a fraction of cellular VCP is contained in the nucleus where 
it is involved in chromatin-associated events and quality control of nuclear proteins (Xia et 
al., 2016). 
 After optimising the conditions for mitochondrial staining using MitoTracker CMX 
Ros, we decided to examine in detail a system in which endogenous levels of either WT-
VCP or VCPR155H were expressed. In order to do this, we isolated and cultured primary 
fibroblasts from our VCPR155H/+ mouse model of IBMPFD, which has been shown by others 
to phenocopy the disease in humans (Badadani et al., 2010). It is important to note that the 
fibroblasts we used to visualise mitochondrial dynamics were isolated from young mice (up 
to 3 months of age). This was due to a lack of older mice in our breeding colony when these 
experiments were carried out. The results of these experiments therefore did not exactly 
represent mitochondrial dynamics in a very aged animal, but do reveal the acute effects of 
oxidative stress on the mitochondrial networks in these cells.  
 Initially, antibodies for endogenous VCP immunodetection proved to be 
insufficiently sensitive, however after optimising several different antibodies, we found an 
anti-VCP antibody which yielded vastly better immunofluorescence staining. The primary 
fibroblasts from WT and VCPR155H mice were incubated with 50um CCCP for three hours – 
a period shown to induce mitochondrial fragmentation but not total cellular apoptosis 
(Yang et al., 2001) – followed by removal of CCCP by rinsing in DMEM and subsequent 
mitochondrial labelling using 300nM MitoTracker CMXRos for 25 minutes. Interestingly, 
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despite the CCCP-induced depolarisation of the mitochondrial membrane potential, the 
individual fragmented mitochondria regained their proton gradient to take in the 
membrane potential-dependent dye, indicating the reconstitution of the proton gradient 
and demonstrating the reversibility of protonophore and the rapid adaptation of 
mitochondria to the removal of an external oxidative stressor. We found that, while the 
mitochondria in both WT-VCP and VCPR155H fibroblasts fragmented following OXPHOS 
uncoupling, VCP distribution became more punctate, however these aggregates did not 
colocalise with the fragmented mitochondria (Figure 4.2).  
 The dynamic nature of mitochondria in the cellular environment and the limitations 
of 2D analysis in terms of accurately deciphering morphological changes in the network 
necessitated a more in-depth examination of the structures in order to determine the 
effects of VCP mutation on the ability of the network to fragment when exposed to 
environmental stresses. Our initial visual analysis led towards investigating the oxidative 
stress-induced morphological changes in the mitochondrial networks of primary fibroblasts 
in a more quantitative manner, as morphological changes in the network impact upon its 
energy-generating capacity (Benard et al., 2006). Continued ATP generation via oxidative 
phosphorylation is necessary to meet the changing metabolic demands of the cell, 
therefore mitochondrial quality control mechanisms must be tightly regulated in order to 
preserve mitochondrial network integrity. Fission and fusion processes allow damaged 
mitochondria to be readily removed from the network and recruited to critical subcellular 
compartments. When these events are compromised, whether through 
dysfunction/inhibited degradation of the fusion proteins or dysregulation of the associated 
proteins involved in the targeting of dysfunctional mitochondrial proteins, catastrophic 
cellular dysfunction ensues (Ashrafi et al., 2013; Tait et al., 2010; Hagen et al., 1997). 
Indeed, mice lacking mitofusin proteins Mfn1 and Mfn2 do not survive beyond mid-
gestation, with homozygous Mfn1 mutation proving to be embryonically lethal (Chen et al., 
2003). Also, disruption of mitochondrial fission through RNA interference or expression of a 
dominant negative variants of Drp1 results in elongated mitochondria that become 
entangled and subsequently collapse into the perinuclear region (Smirnov et al., 2001), 
again underscoring the vital nature of these dynamic mitochondrial characteristics.  
 As previously outlined, the process of mitophagy is essential in the removal of 
aberrant mitochondria from the network. The successful removal of dysfunctional Mfn1 
and Mfn2 from the mitochondrial membrane requires intact VCP and the subsequent 
proteasomal degradation of these proteins prevents re-fusion of damaged mitochondria 
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with the network. Ubiquitination of Mfn1 was found to be increased in Parkin-expressing 
HeLa cells overexpressing the dominant negative ATPase deficient E305Q/E578Q VCP 
mutant (Tanaka et al., 2010). Proteasomal degradation of ubiquitinated Mfn1 was inhibited 
by this expression, indicating that the ATPase function of VCP is required for the 
retrotranslocation of these tagged proteins for degradation. The clinically relevant disease-
associated R155H missense mutation still displays ATPase function (Weihl et al., 2006), 
therefore we wanted to investigate the impact of this mutation in relation to mitochondrial 
fragmentation.  
 Using Imaris analysis software, we converted high magnification Z-stacked 
microscope images into a 3D reconstruction or rendering which could be analysed 
topologically by the software. We were able to quantify, in µm3, the changes occurring in 
network volume in WT-VCP and VCP-R155H under control growth conditions and following 
exposure to oxidative stress. Notably, the volumes of mitochondrial objects were 
significantly smaller in VCPR155H-expressing fibroblasts when compared to WT cells under 
control conditions. The reasons behind this are unclear; one would expect that, if the 
degradation of mitochondrial fusion proteins were affected by the expression of 
VCPR155H, the mitochondrial networks in these cells would be longer, owing to disrupted 
fission. However, it has been demonstrated that intact VCP is required for PINK1/Parkin-
mediated mitochondrial quality control (Kim et al., 2013); therefore it is possible that the 
final degradation of the smaller mitochondria that have been removed from the network 
may be impeded by the expression of dysfunctional VCP. 
 We compared mitochondrial object volumes statistically using an ANOVA on ranks 
with a Tukey post-hoc analysis and, in both WT-VCP and VCPR155H-expressing fibroblasts, 
a significant reduction in mitochondrial volumes following CCCP treatment was observed 
(Figure 4.6). Notably however, several mitochondrial objects with volumes exceeding 100 
µm3 were recorded in VCPR155H-expressing cells (compared with the largest mitochondrial 
object measuring 51.7 µm3 in WT-VCP cells), possibly indicating incomplete fragmentation 
of the network in these cells.  
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Chapter 5 
Discussion 
 
 As described in chapter 1, the AAA+ ATPase, VCP, is involved in a plethora of 
cellular activities, and missense mutations in the encoding gene result in the development 
of IBMPFD, a complex, multisystem disorder, resulting in death of patients. Much research 
has investigated the role of VCP in numerous physiologic and pathologic processes, and the 
availability of disease models of VCP mutation has greatly enhanced our knowledge of the 
aberrant processes in IBMPFD pathological development.  
 The most common presenting symptom in IBMPFD is progressive proximal and 
distal muscle weakness and wasting, evident in patients at approximately 45 years of age. 
Histological analysis of affected muscle reveals variable features of myopathy. The 
heterozygous VCP-R155H mutation in mice results in age-dependent loss of force in 
skeletal muscle, delayed force recovery post-FP and diminished grip strength and Rotarod 
performance. In order to further elucidate the functional impact of VCP mutation on 
skeletal muscle, we used a knock-in VCP mutant mouse model, allowing us to tease out the 
processes involved in the age-related myopathic degeneration and examine the functional 
consequences of VCP mutation within a system. Studies on the knock-in mouse model of 
the disease, in which the R155H mutation is constitutively introduced into one VCP allele, 
have shown abnormal swollen mitochondria, prompting investigation into the effects of 
the mutation on the energy generating capacity of the tissue in response to contractile 
stimulation. Our work was initially directed towards determining whether VCP mutation 
affected force production and prolonged contractile capability, in the context of a 
potentially dysfunctional mitochondrial network. We found that, following a fatigue 
protocol, in which maximal isometric contractions were stimulated in fibre bundles isolated 
from EDL and soleus, fast-twitch fibre bundles from the VCPR155H/+ mouse exhibited reduced 
fatigue tolerance and delayed post-fatigue recovery. This effect of VCP mutation was 
evident only in fast-twitch fibre bundles from aged mice, similar to the age-dependent 
nature of the disease in humans, and reinforcing the phenotypic similarities of the mouse 
model and the human disease. It is important to note that, unlike in humans, the 
106 
 
heterozygous expression of VCPR155H in mice did not result in early death for all animals 
harbouring the mutation, as evidenced by the very aged (27 month old) group of mice 
included in our experiments. It would be of great interest to examine the fibre composition 
of these animals to develop a clearer picture of why and how these animals recover from 
the muscle dysfunction seen in their younger counter parts. 
 Our findings indicate that the ability of fast-twitch muscle in VCPR155H/+ mice to 
generate ATP for prolonged contractile activity is diminished. This may result from the 
reported presence of abnormal mitochondria in VCPR155H/+ mice and IBMPFD patient 
skeletal muscle tissue. As discussed before, ATP is required for contractile cross-bridge 
cycling, and the rate of cross-bridge formation is determined by the levels of ATP in the 
sarcoplasm. Numerous biochemical processes generate ATP, including glycogen and 
glucose metabolism, oxidative phosphorylation, lipid metabolism and creatine kinase-
induced cleavage of phosphocreatine (Milone and Wong, 2013). Glycolysis, in the short 
term, and mitochondrial oxidative phosphorylation, in the longer term, generate ATP for 
contraction in muscle. Maintenance of mitochondrial function is essential for the successful 
generation of energy, therefore, if the mitochondrial network is dysfunctional, and ATP 
generation is compromised, short term contraction will be maintained, but prolonged 
activity may be compromised, as seen in our findings. This theory is supported by the 
observations of Bartolome and colleagues, in which ATP levels were reduced in primary 
fibroblasts isolated from patients harbouring VCP mutations (Bartolome et al., 2013). The 
reduction in ATP generation may also support, and partially explain, the significantly 
prolonged recovery time of VCPR155H/+ fast-twitch fibre bundles after the fatigue protocol. 
Indeed, mitochondrial myopathy commonly manifests as intolerance to exercise and 
premature fatigue (Milone and Wong, 2013). While the EDL is categorised as a fast-twitch 
muscle, experiments on single fibre preparations could further characterise the effects of 
VCP mutation on specific fibre subtypes, based on MHC expression.  
 Earlier studies which characterised myopathic changes in the VCPR155H/+ mouse 
model showed an age-dependent reduction in grip strength and Rotarod performance 
(Badadani et al., 2010; Nalbandian et al., 2012). Interestingly, the researchers found that a 
chronic exercise protocol, involving 30 minutes treadmill running three times per week for 
6 weeks, improved performance in both grip strength and Rotarod (Nalbandian et al., 
2013). Histological analysis of quadriceps muscle tissue from the chronic exercise VCPR155H/+ 
model showed marked improvement in the myopathy, revealing reduced atrophy and 
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fewer centrally located nuclei (indicating a reduction in myofibre degeneration). In 
addition, an increase in succinate dehydrogenase staining in quadriceps muscle was 
observed in the exercised animals, suggestive of an increase in oxidative potential 
(Nalbandian et al., 2013).  
 Skeletal muscle is a highly adaptive tissue, which changes in response to variable 
environmental stimuli. Research has highlighted the benefits of exercise training in the 
context of muscular dystrophy conditions. Exercise is known to play a role in numerous 
processes, such as activation of molecular signalling pathways which stimulate myofibrillar 
protein synthesis and muscle hypertrophy, intracellular calcium handling and increased 
oxidative capacity (Mallinson et al., 2013). The exercise-induced increase in muscle 
strength in VCPR155H/+ mice observed by Nalbandian and colleagues (2015) was 
accompanied by an increase in oxidative potential of the tissue, emphasizing the retained 
ability of this tissue to adapt to external stimuli. As the analysis was conducted on 
quadriceps muscle biopsies, future investigations could include determining whether the 
oxidative capacity of fast- and slow-twitch muscle improves in a similar manner following 
prescription of a chronic exercise regimen. The application of an exercise protocol in early-
stage IBMPFD patients could prove beneficial, however rigorous studies must be 
undertaken to fully assess the impacts of such a protocol on the overall health of 
individuals with muscle dysfunction, as injury propensity, due to myopathic instability and 
loss of strength, is increased. Measurement of mitochondrial enzyme activity showed a 
reduction in fast-twitch muscle from VCPR155H/+ mice at 14 months, concomitant with 
reduced fatigue tolerance and delayed post-fatigue recovery. 
 The process of aging is accompanied by a gradual loss of muscle mass and 
subsequently functional capacity, known as sarcopenia (Rosenberg, 1997). However, many 
cellular and molecular changes occur in muscle fibres as individuals age. A decrease in 
muscle fibre number and size (predominantly type II fibres), reduced myosin protein 
content and function, calcium release deficits and disrupted excitation-contraction coupling 
all contribute to the overall loss of skeletal muscle integrity and function that is seen during 
the aging process (Lexell, 1995; D’Antona et al., 2003; Russ et al., 2011; Miljkovic et al., 
2015). Interestingly, the reduction in fibre size is fibre type-specific, with type II fibres 10-
40% smaller in elderly individuals compared with young controls (Lexell, 1995). In contrast, 
type I fibre size remains largely unchanged. This age-dependent change can be explained 
by age-associated remodelling of the motor unit structure, whereby type II fibres become 
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denervated and type I fibres are re-innervated. Conversely, our research has demonstrated 
an increase in fast-oxidative and fast-glycolytic fibre size in 12 month old VCPR155H/+ EDL 
when compared with wild-type controls (Figure 3.11). However, at 14 months, 
intermediate (fast-oxidative-glycolytic) fibres are significantly smaller in the VCPR155H/+ EDL. 
No clear pattern in fast-twitch fibre size alteration was observed in analysis using 
cryosections, an observation also made by Hübbers and colleagues (2006). One possible 
explanation for the increased fibre size may be the presence of rimmed vacuoles in muscle 
fibres, as seen in a skeletal muscle biopsy taken from a patient harbouring the VCP-R93C 
mutation (Hübbers et al., 2006). While these rimmed vacuoles and inclusion bodies have 
been observed in the muscle of VCP mutant mice by other groups (Figure S.6.; Badadani et 
al., 2010; Custer et al., 2010; Nalbandian et al., 2013), we did not encounter this 
phenomenon in our animals.  
 An interesting finding of our work was the apparent absence of fatigue-intolerance 
in very aged (27 month old) VCPR155H/+ mice when compared with WT controls. One 
potential explanation for this may lie in the reported protective effects of chronic low level 
mitochondrial stress in skeletal muscle. Chronic oxidative stress, and the resulting 
production of reactive oxygen species (ROS), has long been purported to be the underlying 
cause of aging (Harman, 1956). However, reports have presented conflicting evidence of 
the effect of chronic oxidative stress on cells. In fact, it is now generally accepted that 
treatment aimed at reducing the levels of free radicals in cells, namely antioxidant therapy, 
is ineffective, and may be harmful to the overall population (Miller, 2005). Studies have 
attempted to elucidate the mechanisms by which low levels of stress, particularly oxidative 
stress in the mitochondrion, induce adaptive cryoprotective signalling responses (Owusu-
Ansah et al., 2013). Mitochondrial perturbation and dysfunction results in the production 
of ROS, therefore it may be possible that the very aged mice in our study were subjected to 
low level chronic oxidative stress over their lifespan, and as such, developed adaptive 
mechanisms to counteract this stress, thus promoting longevity in these animals. If this was 
the case, the skeletal muscle fatigue-tolerance of these animals may be preserved, 
however this theory requires much further investigation. 
 The dynamic nature of the mitochondrial network dictated that several methods of 
examination were required to uncover possible effects of VCP mutation on mitochondrial 
fusion and fission events. Immunofluorescent labelling of endogenous VCP in primary cells 
from VCPR155H/+ mice in conjunction with live staining of the mitochondrial networks 
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enabled us to visualise localisation of VCP in relation to the networks under both steady-
state and stressful conditions. The translocation of VCP to mitochondria upon uncoupling 
has been shown in HeLa cells (Tanaka et al., 2010), however this process was shown to be 
dependent on the transient expression of the E3-ub ligase Parkin, which is expressed at 
varying levels in different cell types with high expression observed in neuronal cells and 
negligible amounts seen in others (Matsuda et al., 2010). Endogenous Parkin expression 
was determined in WT and VCP-R155H primary fibroblasts, showing significantly lower 
expression when compared with a WT brain lysate (Figure 4.3). Neither wild type nor 
mutated VCP was shown to colocalise with uncoupled mitochondria in primary fibroblasts 
from WT and VCPR155H/+ mice (Figure 4.2), further emphasising the Parkin-dependence of 
this translocation. Indeed, Kimura et al. demonstrated the colocalisation of WT-VCP with 
the mitochondria in Parkin-expressing HeLa cells upon CCCP-induced uncoupling of the 
mitochondrial membrane potential. However, pathogenic EGFP-VCP-R155H, transfected 
into MEF cells, remained diffusely distributed throughout the cytoplasm of these cells in 
response to the uncoupling agent. We have shown that in fibroblast cells, which lack high 
Parkin expression, neither WT nor pathogenic R155H-mutated VCP respond to disruption of 
mitochondrial membrane potential and subsequent fragmentation of the network. It is 
important to note that in skeletal muscle, parkin gene (Kitada et al., 1998) and protein 
expression (Van Humbeek et al., 2008) are similar to that in brain tissue, therefore this may 
impact upon the localisation of VCP in relation to the mitochondrial network in skeletal 
muscle tissue. 
 Recently, Nalbandian and colleagues have studied the mitochondrial bioenergetics 
of primary myoblasts, isolated from both IBMPFD patients and the VCPR155H/+ mouse 
disease model. Basal respiration, proton leak, ATP turnover and both spare and maximal 
respiratory capacity were measured, using the Seahorse Metabolic Flux Analyser. The 
experiments revealed decreased ATP levels, spare respiratory capacity and increased 
proton leak in VCP-deficient cells, indicating a loss of mitochondrial membrane integrity. 
Again, future studies might utilise this technique to assess how mitochondrial bioenergetics 
in VCP-mutant mice are affected following the application of a chronic exercise protocol. 
This would clearly demonstrate the specific components of the mitochondrial respiratory 
chain that are adapting and improving skeletal muscle performance in these animals 
(Nalbandian et al., 2013). 
110 
 
 Mitochondria are a major source of free radicals, or reactive oxygen species (ROS) 
within the cell. It is estimated that between 0.4-4.0% of the oxygen used during ATP 
generation in the cell is converted to superoxide radicals by mitochondria (Pieczenik and 
Neustadt, 2007). Mitochondrial dysfunction has been implicated in a melange of acquired 
conditions and pathologies, such as diabetes, cancer, Huntington’s disease, Alzheimer’s 
disease,  Parkinson’s disease, aging and cardiovascular disease (Stavrovskaya and Kristal, 
2005; Fosslien et al., 2001; Wallace et al., 2005). Our work has uncovered mitochondrial 
fission deficits in the VCPR155H/+ mouse model, which may lead to impaired mitochondrial 
dynamics and subsequent cellular dysfunction and death. Interestingly, symptoms of 
mitochondria-related disorders typically develop over years, and it is uncommon for these 
disorders to be diagnosed when symptoms first present (Cohen and Gold, 2001), as is 
generally the case with IBMPFD patients. Mitochondrial dysfunction may affect any tissue 
in the body, therefore the pathologic consequences in each tissue type may appear very 
distinct, again, as observed in the variety of pathological penetrance in IBMPFD patients.  
 This work served to underscore the hypothesis that VCP mutant-induced 
mitochondrial dysfunction results in decreased contractile activity in skeletal muscle, the 
primary tissue affected by mutations in the VCP gene.  Further investigations have 
implicated dysfunctional VCP in mitochondrial deficits in neuronal cells types (Fang et al., 
2015), as failure to maintain mitochondrial health is central to neurodegeneration 
(Karbowski and Neutzner, 2012). Quality control of membrane-bound proteins involves 
their extraction from the membrane and retrotranslocation into the cytosol for 
degradation. VCP is a key player in this process, as has been evidenced by its role in ERAD 
(Wolf and Stolz, 2012). Our research has added to the ever-growing cellular repertoire of 
VCP.  
 Despite significant progress in delineating the numerous cellular functions of VCP 
and characterising the pathological consequences of VCP mutation, there are currently no 
therapeutic strategies for IBMPFD patients (Nalbandian et al., 2013). Several studies have 
provided evidence of the beneficial effects of exercise training in muscular dystrophy 
conditions, due to its critical role in cellular processes such as signalling pathway activation, 
intracellular calcium movements and increased antioxidant capacity. Chronic exercise 
training was shown to improve the myopathy in the VCPR155H/+ mouse model (Nalbandian et 
al., 2013). The authors demonstrated that autophagy was intact in the exercised animals, 
as evidenced by a decrease in typical autophagy marker proteins, such as ubiquitin, p62 
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and LC3-II, which accumulate in the VCPR155H/+ mouse model under homeostatic conditions. 
Following the exercise regimen, a decrease in the ubiquitin- and TDP-43-positive inclusions 
has been observed, which suggests the cytotoxic proteinaceous aggregates are being 
broken down. The authors suggest that the exercise-induced depletion of ATP and the 
resulting upregulation of the AMP-activated protein kinase (AMPK) pathway increases 
autophagic proteolysis via inhibition of the mTOR pathway, thus clearing, at least in part, 
the accumulated cellular debris. Application of a long-term exercise protocol may therefore 
help to delay IBMPFD myopathic degeneration by both improving mitochondrial function 
and increasing AMPK-mediated aggregate clearance.  
 It is important to recognise some of the limitations with the present work. Caution 
is required when extrapolating data obtained from studies of genetically modified animals 
in order to investigate the effects of a disease on muscle function in humans. For example, 
there are large differences in phenotypic expression and biomechanical properties of the 
dystrophic disease in humans and the mdx mouse, therefore translational gaps exist in this 
model (Duan, 2015). Mice, unlike humans, are quadrapedal, therefore the stresses and 
force exerted on skeletal muscles in mice differ from that in humans. Nonetheless, smaller 
animal models, such as mice, provide an extremely useful tool for the initial investigation 
into and analysis of the molecular basis of a disease in humans. Our work was also limited 
by the small n numbers used in the muscle mechanics experiments. Ideally, a higher n 
number would have strengthened the statistical power, reduced the standard error and 
decreased the likelihood of incurring a type I error in our results.  
 In summary, our research into the biomechanical and physiological consequences 
of VCP mutation in an animal model of the clinically relevant disorder IBMPFD supports the 
emerging theory that VCP plays an integral role in mitochondrial maintenance, and 
heterozygous expression of the IBMPFD mutant, VCP-R155H, results in mitochondrial 
deficits which present symptomatically as fatigue intolerance and delayed recovery in fast-
twitch skeletal muscle.  
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Supplementary data 
 
 
 
 
 
Figure S.1 Analysis of VCPR155H/+ knock-in mouse genotype. (i) PCR protocol resulted in the 
generation of DNA fragments of 982bp in size. (ii) Restriction enzyme digestion of PCR 
products with Nco1 resulted in three DNA fragments (982bp, 700bp and 282bp) in the 
heterozygous VCPR155H/+ mouse extracts only 
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Figure S.2. Plasmid map of EGFP-tagged WT-VCP including restriction sites. 
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Figure S.3. Plasmid map of EGFP-tagged VCPR155H with restriction sites. 
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Figure S.4. Fatigue-induced changes in tetanic contraction characteristics in aged 
VCP
R155H/+
 fast-twitch fibre bundles. Average tetanic relaxation time of age-matched WT 
and VCP
R155H/+
 fast-twitch fibre bundles prior to fatigue protocol (Pre-FP; closed circles) and 
at the end of the fatigue protocol (End-FP; open triangles). Graph represents the average of 
three tetanic contractions pre-FP and the final three contractions of the FP ±SEM. At 14 
months (Group 3), VCP
R155H/+
 fast-twitch fibre terminal-FP tetanic relaxation times were 
significantly faster than pre-FP tetanic relaxation times (0.1430.013 sec compared to 
0.1860.012 sec respectively, P<0.05). 
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Figure S.5 Immunostained cryosections of (A) soleus and (B) EDL. Antibodies raised 
against MHC type I and all isoforms of MHC type II were used to confirm that all fibres in 
EDL were MHC type II. Note, as all fibres in EDL were found to be type II, a cryosection of 
soleus is used to show the contrast between MHC-F- and MHC-S-positive fibres. Nidogen-
1(red) antibody was used to stain the basement membrane. (Scale bars: 100µm). 
Merge 
Nidogen-1 
MHC-F 
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Figure S.6 Comparison of skeletal muscle pathology in (A) IBMPFD patient biopsy and (B) 
VCPR155H-mutant mouse. (A) Biopsy of muscle taken from IBMPDF patient which has 
been stained using a polyclonal VCP antibody. Large focal inclusion (arrow) in the muscle 
fibre contains VCP. (B) Modified Gomori Trichrome staining of quadricep section from 
VCPR155H/+ knock-in mouse shows the presence of rimmed vacuoles (indicated by black 
arrow) (images taken from Watts et al., 2004 (A) and Badadani et al., 2010 (B)). 
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